Global Contraceptive Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Global Contraceptive Market, By Product Type (Contraceptive Drugs, Contraceptive Devices, Contraceptive Spermicides & Adjunct Products), By Hormonal Composition (Estrogen + Progestin Combination Contraceptives, Progestin-Only Contraceptives, Non-Hormonal Contraceptives, Other Hormonal Contraceptives), By Duration of Action (Short-Acting Reversible Contraceptives, Intermediate-Acting Contraceptives, Long-Acting Reversible Contraceptives (LARC), Permanent Contraception), By Route of Administration (Oral, Injectable, Transdermal, Vaginal, Intrauterine, Subdermal, External Application, Other Routes), By Gender (Female Contraceptives, Male Contraceptives), By Prescription Status (Prescription Contraceptives, Over-the-Counter (OTC) Contraceptives), By Age Group (Adolescents (10-19 Years), Young Adults (20-29 Years), Adults (30-44 Years), Older Reproductive-Age Population (45-49 Years)), By End User (Hospitals, Gynecology & Obstetric Clinics, Family Planning Centers, Community Health Centers, Individual / Home Users), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies, Direct / Institutional Sales) - Industry Trends and Forecast to 2033

Forecast Period 2026 - 2033

CAGR 2.40%

2025 Market Size USD 8.67 Billion

2033 Market Size USD 10.49 Billion

Market Size Trend

2025 USD 8.67 Billion

2029 USD 9.53 Billion

2033 USD 10.49 Billion

Regional Dominance

Market Coverage Global

Key Players

Bayer AG (Germany)
Organon & Co. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Pfizer Inc. (U.S.)
Gedeon Richter Plc. (Hungary)

Healthcare
Global
350 Pages
No of Tables: 1333
No of Figures: 96
Author :

What is the Contraceptive Market Size and Growth Rate?

As per Data Bridge Market Research Analysis the global contraceptive market was valued at USD 8.67 billion in 2025 and is projected to reach USD 10.49 billion by 2033, growing at a CAGR of 2.40% from 2026 to 2033. Contraceptives include pharmaceutical products and medical devices, such as oral contraceptive pills, injectable contraceptives, condoms, intrauterine devices (IUDs), implants, patches, vaginal rings, and emergency contraceptives. Growing demand for convenient, reliable, and reversible birth control methods is supporting market development across diverse population groups. Increasing access to reproductive healthcare services, government-supported family planning programs, and educational campaigns is further contributing to the adoption of contraceptive products.

Furthermore, advancements in contraceptive formulations, growing interest in long-acting reversible contraceptives, and expanding distribution through retail pharmacies, healthcare facilities, and online platforms are creating opportunities for market participants. Pharmaceutical companies and medical device manufacturers are focusing on product innovation, improved user convenience, and broader access to contraceptive options. However, affordability barriers, social stigma, regulatory differences, and disparities in healthcare access continue to influence market development. Increasing emphasis on reproductive health education and family planning is expected to support the growth of the Global Contraceptive Market during the forecast period.

Market Size & Forecast

Global Market Value (2025): USD 8.67 billion
Expected Market Value (2033): USD 10.49 billion
Forecast CAGR (2026–2033): 2.40%
Leading Region in 2025: North America
Fastest Growing Region: Middle East & Africa

Key Market Trends & Insights

The North America region dominated the global contraceptive market with the largest revenue share of 39.28% in 2025, supported by established healthcare infrastructure, increasing awareness of reproductive health, and widespread availability of contraceptive products. Strong access to family planning services, retail pharmacies, and prescription-based healthcare, along with growing adoption of modern contraceptive methods, further strengthened regional market demand.
The contraceptive drugs segment dominated the market with a 47.21% share in 2025, driven by the widespread use of oral contraceptive pills, injectable contraceptives, and emergency contraceptive drugs. Their availability through pharmacies and healthcare facilities, ease of administration, and suitability for different reproductive health needs supported the segment's leading position.
The Middle East and Africa region is expected to be the fastest-growing region in the global contraceptive market, registering a CAGR of 3.95% during 2026–2033. Growth is supported by increasing awareness of family planning, expanding reproductive healthcare initiatives, and improving access to contraceptive products. Government programs and healthcare organizations promoting pregnancy prevention are further contributing to regional market development.
The progestin-only contraceptives segment dominated the market with a 43.34% share in 2025, supported by demand for hormonal contraceptive options that do not contain estrogen. Their availability in different formulations, including pills, injectables, and implants, provides flexibility for users with varying contraceptive needs and supports adoption across reproductive healthcare settings.
The short-acting reversible contraceptives segment dominated the market with a 62.48% share in 2025, owing to the widespread use of oral contraceptive pills, condoms, and other reversible birth control methods. Their accessibility, convenience, and flexibility in discontinuation support adoption among individuals seeking pregnancy prevention options that can be managed according to personal preferences and family planning needs.
The oral segment dominated the market with a 36.96% share in 2025, driven by the widespread adoption of oral contraceptive pills and their convenient administration. The availability of combined and progestin-only formulations, established consumer familiarity, and broad distribution through pharmacies and healthcare providers continue to support demand for oral contraceptive products.
The female contraceptives segment dominated the market with an 81.85% share in 2025, supported by the broad availability of established contraceptive options, including oral pills, injectables, implants, intrauterine devices, patches, and vaginal rings. Increasing awareness of reproductive health, access to family planning services, and demand for effective pregnancy prevention methods further strengthened the segment's leading position.

Report Scope and Contraceptive Market Segmentation

Attributes	Contraceptive Key Market Insights
Segments Covered	By Product Type: Contraceptive Drugs, Contraceptive Devices, Contraceptive Spermicides & Adjunct Products By Hormonal Composition: Estrogen + Progestin Combination Contraceptives, Progestin-Only Contraceptives, Non-Hormonal Contraceptives, Other Hormonal Contraceptives By Duration of Action: Short-Acting Reversible Contraceptives, Intermediate-Acting Contraceptives, Long-Acting Reversible Contraceptives (LARC), Permanent Contraception By Route of Administration: Oral, Injectable, Transdermal, Vaginal, Intrauterine, Subdermal, External Application, Other Routes By Gender: Female Contraceptives, Male Contraceptives By Prescription Status: Prescription Contraceptives, Over-the-Counter (OTC) Contraceptives By Age Group: Adolescents (10-19 Years), Young Adults (20-29 Years), Adults (30-44 Years), Older Reproductive-Age Population (45-49 Years) By End User: Hospitals, Gynecology & Obstetric Clinics, Family Planning Centers, Community Health Centers, Individual / Home Users By Distribution Channel: Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies, Direct / Institutional Sales
Countries Covered	North America U.S. Canada Mexico Europe Germany U.K. France Italy Spain Russia Turkey Netherlands Belgium Sweden Norway Denmark Finland Switzerland Rest of Europe Asia-Pacific China India Japan South Korea Indonesia Thailand Malaysia Australia Philippines Taiwan Singapore New Zealand Hong Kong Rest of Asia-Pacific South America Brazil Argentina Peru Chile Colombia Ecuador Venezuela Uruguay Paraguay Bolivia Rest of South America Middle East and Africa Saudi Arabia United Arab Emirates South Africa Egypt Israel Qatar Oman Kuwait Bahrain Rest of Middle East and Africa
Key Market Players	Bayer AG (Germany) Organon & Co. (U.S.) Teva Pharmaceutical Industries Ltd. (Israel) Pfizer Inc. (U.S.) Gedeon Richter Plc. (Hungary) Viatris Inc. (U.S.) Sun Pharmaceutical Industries Ltd. (India) Lupin (India) Glenmark Pharmaceuticals (India) Cipla (India) Apotex Inc. (Canada) Insud Pharma, S.L. (Spain) CooperSurgical, Inc. (U.S.) Pregna International Limited (India) SMB Corporation of India (India) Eurogine (Spain) OCON Medical Ltd. (Israel) Shanghai Dahua Pharmaceutical Co., Ltd. (China) Church & Dwight Co., Inc. (U.S.) Reckitt (U.K.) Okamoto Industries, Inc. (Japan) Sagami Rubber Industries Co., Ltd. (Japan) Fuji Latex Co., Ltd. (Japan) Karex Berhad (Malaysia) Thai Nippon Rubber Industry Public Company Limited (Thailand) Mayer Laboratories, Inc. (U.S.) HLL Lifecare Limited (India) Cupid Limited (India) TTK Healthcare Limited (India) Mankind Pharma Limited (India)
Market Opportunities	Advances in novel contraceptive technologies (LARC, non-hormonal) Growth in developing regions with low penetration Self-injection and over-the-counter pills moving contraception out of the clinic A male contraception pipeline approaching its first pivotal trial
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

What is the Key Trend in the Contraceptive Market?

Trend: Advancements in Contraceptive Formulations and Expansion of Long-Acting Reversible Contraceptives

The global contraceptive market is increasingly focusing on product innovation, improved user convenience, and the development of diverse contraceptive options to address changing reproductive healthcare needs. Manufacturers are advancing hormonal formulations, reusable vaginal contraceptive systems, transdermal patches, and long-acting reversible contraceptives (LARCs) to provide individuals with more flexible pregnancy prevention options. Growing awareness of family planning, increasing demand for non-daily contraceptive methods, and expanding access to reproductive healthcare services are supporting product development across the market. In addition, research into non-hormonal contraception and male contraceptive options is broadening the scope of innovation. Collaborations between pharmaceutical companies, medical device manufacturers, and research organizations are further supporting the development and commercialization of new contraceptive technologies.

For instance,

In July 2026, Viatris Inc.received U.S. FDA approval for Gwyn Lo, a once-weekly combined hormonal contraceptive patch containing norelgestromin and ethinyl estradiol. The product introduced a low-dose estrogen option for eligible women seeking a reversible, non-invasive contraceptive method.
In April 2026, Duchesnay launched Ringza in Canada in collaboration with the Population Council. The reusable contraceptive vaginal system is designed for use for up to one year, providing a patient-controlled and reversible alternative to contraceptive methods requiring more frequent administration.
In February 2026, Contraline and the Population Council entered into a global exclusive licensing agreement for the NEST male contraceptive gel. The once-daily topical formulation combines segesterone acetate with testosterone and is being developed as a reversible hormonal contraceptive option for men.

Overall, these developments highlight the growing importance of contraceptive innovation, user convenience, and diversification of available birth control methods in the global contraceptive market. The introduction of new delivery systems, including weekly patches and reusable vaginal rings, is expanding options for women, while research into male contraceptives is addressing unmet needs in reproductive healthcare. Continued investment in research and development, regulatory approvals, and collaborations between pharmaceutical companies and research organizations is expected to support product innovation and market growth during the forecast period.

Contraceptive Market Dynamics

Key Market Driver: Growing Demand for Convenient Contraceptive Options and Advancements in Reproductive Healthcare

The global contraceptive market is increasingly focusing on developing convenient, effective, and user-friendly contraceptive options to address diverse reproductive health needs. Manufacturers are expanding product portfolios across oral contraceptive pills, vaginal rings, contraceptive patches, intrauterine devices (IUDs), implants, and other hormonal and non-hormonal methods. Growing awareness of family planning, increasing demand for reversible contraception, and improvements in reproductive healthcare access are supporting the adoption of modern contraceptive products. In addition, advancements in contraceptive formulations, extended-duration protection, and alternative delivery systems are creating opportunities for product innovation. Pharmaceutical companies and healthcare organizations are also exploring new approaches to male contraception, non-hormonal birth control, and improved user convenience. These developments are encouraging manufacturers to strengthen research and development activities and broaden access to contraceptive options across different markets.

For instance,

In October 2025, the Australian Government announced improved access to affordable contraceptive options through the Pharmaceutical Benefits Scheme (PBS), including the listing of NuvaRing from 1 November 2025. The initiative aimed to reduce costs and expand access to alternatives to daily oral contraceptive pills.
In February 2026, Contraline and the Population Council executed a global exclusive licensing agreement for the NES/T male contraceptive gel. The agreement supported the transition of the investigational product toward late-stage development and future regulatory evaluation, highlighting progress in expanding reversible male contraceptive options.
In April 2026, Duchesnay announced the Canadian launch of Ringza, a reusable contraceptive vaginal system developed in collaboration with the Population Council. Designed for use for up to 13 menstrual cycles, the product highlighted the growing focus on patient-controlled contraception and longer-duration contraceptive solutions.
In September 2026, the World Health Organization (WHO) introduced guidance aimed at expanding access to safe and effective contraceptive methods, including future male contraceptives. The initiative highlighted the importance of broadening contraceptive choices, supporting informed decision-making, and encouraging innovation in reproductive healthcare.

Overall, these developments highlight the growing importance of contraceptive innovation, affordability, convenience, and expanded access to reproductive healthcare in the global contraceptive market. Increasing demand for patient-controlled products, reusable delivery systems, and new male contraceptive options is encouraging pharmaceutical companies and healthcare organizations to invest in product development and accessibility initiatives. Continued advancements in contraceptive technologies, alongside supportive healthcare policies and family planning programs, are expected to support market development during the forecast period.

Key Restraint/Challenge: Growing Demand for Innovative Contraceptive Methods and Improved Accessibility

The Global Contraceptive Market is increasingly focusing on the development of innovative contraceptive methods, improved product convenience, and expanded access to reproductive healthcare. Manufacturers are developing advanced hormonal formulations, long-acting reversible contraceptives (LARCs), and non-hormonal alternatives to address diverse user preferences and reproductive health requirements. Growing awareness of family planning, the prevention of unintended pregnancies, and the importance of reproductive health is supporting the adoption of oral contraceptive pills, vaginal rings, intrauterine devices (IUDs), implants, and contraceptive patches. In addition, improvements in drug delivery technologies, product design, and digital healthcare services are helping improve user convenience and access to contraceptive information. Increasing interest in hormone-free options and male contraceptive research is further encouraging innovation across the market.

For instance,

In April 2026, Duchesnay introduced Ringza, a reusable contraceptive vaginal system in Canada, in collaboration with the Population Council. The launch highlighted continued innovation in vaginal contraceptive delivery and the development of reusable options for pregnancy prevention.
In February 2026, Contraline and the Population Council entered into a global exclusive licensing agreement for a male contraceptive gel. The agreement highlighted ongoing research into additional male contraceptive options and efforts to broaden the range of available birth control methods.
In June 2025, ASKA Pharmaceutical launched Slinda 28 Tablets, a drospirenone-based oral contraceptive, in Japan. The launch reflected continued development and commercialization of hormonal contraceptive options to address women's reproductive healthcare needs.

Overall, these developments highlight the growing importance of contraceptive innovation, user convenience, and broader access to reproductive healthcare in the Global Contraceptive Market. Increasing demand for reliable and reversible birth control methods is encouraging manufacturers to invest in improved formulations, alternative delivery systems, and new contraceptive technologies. Continued product development, public health initiatives, and collaboration between pharmaceutical companies and reproductive health organizations are expected to support market growth during the forecast period.

Key Market Opportunity: Growing Demand for Innovative Contraceptive Methods and Expanded Reproductive Healthcare Access

The global contraceptive market is increasingly focusing on the development of innovative contraceptive methods, improved user convenience, and expanded access to reproductive healthcare services. Manufacturers are developing advanced hormonal and non-hormonal contraceptive products, including oral contraceptive pills, vaginal rings, patches, intrauterine devices (IUDs), and long-acting reversible contraceptives (LARCs), to address diverse reproductive health needs. Growing awareness of family planning, rising demand for effective pregnancy prevention, and increasing interest in user-controlled contraceptive options are supporting product adoption. In addition, advances in contraceptive formulations, reusable delivery systems, and male contraceptive research are creating opportunities for product innovation. Collaborations among pharmaceutical companies, healthcare organizations, and research institutions are further supporting the development and commercialization of new contraceptive solutions.

For instance,

In June 2025, ASKA Pharmaceutical launched Slinda 28 Tablets, a drospirenone-based, progestin-only oral contraceptive in Japan. The launch expanded the availability of contraceptive options and highlighted the continued development of hormonal products designed to address diverse reproductive healthcare needs.
In October 2025, ASKA Pharmaceutical obtained marketing authorization for NORLEVO as an over-the-counter emergency contraceptive in Japan, with Daiichi Sankyo Healthcare preparing to handle distribution and sales. The development highlighted efforts to improve access to emergency contraception and broaden the availability of pregnancy-prevention options.
In September 2026, the World Health Organization (WHO) published its first target product profiles for novel male contraceptive methods. The guidance outlined development priorities related to safety, effectiveness, reversibility, acceptability, and affordability, supporting research into additional contraceptive options for men.

Overall, these developments highlight the growing importance of contraceptive innovation, expanded product accessibility, and diversification of reproductive healthcare options in the global contraceptive market. Increasing demand for convenient oral contraceptives, accessible emergency contraception, and potential male contraceptive methods is encouraging pharmaceutical companies and research organizations to expand their product portfolios and development pipelines. Continued investment in research, improved distribution channels, and greater awareness of family planning are expected to support market development during the forecast period.

How is the Contraceptive Market Segmented?

The global contraceptive market is segmented into eight notable segments based on product type, hormonal composition, duration of action, route of administration, gender, prescription status, age group, end user, and distribution channel.

By product type

On the basis of product type, the global contraceptive market is segmented into contraceptive drugs, contraceptive devices, and contraceptive spermicides & adjunct products. In 2025, the contraceptive devices segment is expected to dominate the global contraceptive market with a market share of 52.31%, driven by the growing demand for reliable pregnancy prevention methods, increasing awareness of reproductive health, and the availability of diverse products such as condoms, intrauterine devices (IUDs), contraceptive implants, and diaphragms. Their effectiveness, accessibility, and suitability for different reproductive health needs are supporting segment growth.

The contraceptive devices segment is projected to register the fastest CAGR of 2.97% from 2026 to 2033, owing to increasing demand for non-hormonal contraceptive options, rising adoption of long-acting reversible contraceptives, and continuous improvements in product design, safety, and user convenience. Expanding family planning initiatives, improved access to reproductive healthcare services, and growing awareness of different contraceptive methods are also expected to support segment growth during the forecast period.

By hormonal composition

On the basis of hormonal composition, the global contraceptive market is segmented into estrogen + progestin combination contraceptives, progestin-only contraceptives, non-hormonal contraceptives, and other hormonal contraceptives. In 2025, the progestin-only contraceptives segment is expected to dominate the global contraceptive market with a market share of 43.34%, driven by increasing demand for estrogen-free contraceptive options, growing awareness of reproductive health, and the availability of diverse formulations, such as progestin-only pills, injections, and implants. Their suitability for individuals who cannot use estrogen-containing contraceptives, along with expanding access through healthcare providers and pharmacies, is supporting segment growth.

The other hormonal contraceptives segment is projected to register the fastest CAGR of 5.83% from 2026 to 2033, owing to ongoing innovation in hormonal delivery systems, increasing demand for convenient and effective pregnancy prevention methods, and growing interest in alternatives to conventional oral contraceptive pills. Advancements in formulations and delivery methods, combined with rising awareness of personalized contraceptive choices and improved access to reproductive healthcare services, are expected to create further growth opportunities for this segment during the forecast period.

By duration of action

On the basis of duration of action, the global contraceptive market is segmented into short-acting reversible contraceptives, intermediate-acting contraceptives, long-acting reversible contraceptives (LARC), and permanent contraception. In 2025, the short-acting reversible contraceptives segment is expected to dominate the global contraceptive market with a market share of 62.48%, owing to the widespread availability of oral contraceptive pills, condoms, and emergency contraceptives, along with their affordability, convenience, and flexibility of use. Growing awareness of pregnancy prevention, easy access through retail pharmacies and online platforms, and the ability to discontinue or change methods according to individual reproductive plans are further supporting segment dominance.

The long-acting reversible contraceptives (LARC) segment is expected to experience the fastest CAGR of 3.73% from 2026 to 2033, owing to increasing demand for highly effective, long-term pregnancy prevention methods, such as intrauterine devices (IUDs) and contraceptive implants. Their extended duration of protection, reduced need for frequent administration, and reversibility are encouraging adoption among individuals seeking convenient family planning options. Increasing healthcare provider recommendations, improved awareness of LARC methods, and expanding access to reproductive health services are also expected to support segment growth during the forecast period.

By route of administration

On the basis of route of administration, the global contraceptive market is segmented into oral, injectable, transdermal, vaginal, intrauterine, subdermal, external application, and other routes. In 2025, the Oral segment is expected to dominate the global contraceptive market with a market share of 36.96%, owing to the widespread availability of oral contraceptive pills, ease of administration, and convenience for routine pregnancy prevention. The availability of combination and progestin-only formulations, established distribution networks through retail pharmacies and online platforms, and growing awareness of reproductive health are further supporting segment dominance. In addition, the ability to discontinue oral contraceptives without a clinical procedure and the availability of different formulations to meet individual healthcare needs are contributing to their continued adoption.

The subdermal segment is expected to experience the fastest CAGR of 4.39% from 2026 to 2033, owing to increasing demand for long-acting, reversible, and highly effective contraceptive methods, particularly contraceptive implants placed beneath the skin. These implants provide extended pregnancy prevention without requiring daily administration, making them a convenient option for individuals seeking reliable family planning solutions. Growing awareness of long-acting reversible contraceptives (LARCs), increasing healthcare provider recommendations, and improvements in implant design and insertion techniques are further supporting adoption.

By gender

On the basis of gender, the global contraceptive market is segmented into female contraceptives and male contraceptives. In 2025, the female contraceptives segment is expected to dominate the global contraceptive market with a market share of 81.85%, owing to the wide availability of contraceptive options designed for women, including oral contraceptive pills, injectable contraceptives, intrauterine devices (IUDs), implants, patches, and vaginal rings. Growing awareness of reproductive health, increasing emphasis on pregnancy prevention and family planning, and established access to female contraceptive products through healthcare facilities and pharmacies are further supporting segment dominance.

The female contraceptives segment is expected to experience the fastest CAGR of 2.60% from 2026 to 2033, owing to continued demand for effective and convenient pregnancy prevention methods, rising awareness of family planning, and ongoing advancements in hormonal formulations and contraceptive delivery systems. Increasing adoption of long-acting reversible contraceptives, expanding reproductive healthcare services, and government-supported family planning initiatives are also expected to support segment growth during the forecast period.

By prescription status

On the basis of prescription status, the global contraceptive market is segmented into prescription contraceptives and over-the-counter (OTC) contraceptives. In 2025, the prescription contraceptives segment is expected to dominate the global contraceptive market with a market share of 77.08%, owing to the widespread use of prescription-based hormonal contraceptives, including oral pills, injectable contraceptives, and certain contraceptive implants. The need for healthcare provider consultations, suitability assessments, and medical guidance for selecting appropriate contraceptive methods is supporting demand for prescription products.

The prescription contraceptives segment is expected to experience the fastest CAGR of 2.56% from 2026 to 2033, owing to increasing demand for medically guided family planning solutions, growing awareness of contraceptive safety and effectiveness, and continued adoption of hormonal contraceptive methods. Expanding access to reproductive healthcare services, rising healthcare provider recommendations, and improvements in contraceptive formulations are expected to support the adoption of prescription-based products.

By age group

On the basis of age group, the global contraceptive market is segmented into adolescents (10–19 years), young adults (20–29 years), adults (30–44 years), and the older reproductive-age population (45–49 years). In 2025, the adults (30–44 Years) segment is expected to dominate the global contraceptive market with a market share of 52.38%, owing to the growing need for effective pregnancy prevention, birth spacing, and family planning among individuals in this age group. Established awareness of reproductive health, continued demand for reliable contraceptive methods, and the availability of diverse options, including oral contraceptive pills, intrauterine devices (IUDs), implants, and injectable contraceptives, are supporting segment dominance.

The young adults (20–29 Years) segment is expected to experience the fastest CAGR of 3.28% from 2026 to 2033, owing to increasing awareness of reproductive health, rising demand for convenient pregnancy prevention methods, and growing emphasis on delaying parenthood. Greater access to contraceptive information through digital healthcare platforms, educational initiatives, pharmacies, and reproductive health services is encouraging adoption among young adults.

By end user

On the basis of end user, the global contraceptive market is segmented into hospitals, gynecology & obstetric clinics, family planning centers, community health centers, and individual / home users. In 2025, the individual / home users segment is expected to dominate the global contraceptive market with a market share of 45.76%, owing to the growing preference for convenient, accessible, and user-controlled pregnancy prevention methods. The widespread availability of oral contraceptive pills, condoms, and over-the-counter contraceptive products through retail pharmacies and online platforms is supporting adoption among individual consumers. Increasing awareness of reproductive health, the preference for privacy when purchasing contraceptives, and growing access to self-administered contraceptive options are further contributing to segment dominance.

The gynecology & obstetric clinics segment is expected to experience the fastest CAGR of 3.27% from 2026 to 2033, owing to increasing demand for professional contraceptive counselling, personalized family planning guidance, and medically supervised contraceptive procedures. These clinics provide access to a broad range of contraceptive methods, including intrauterine devices (IUDs), implants, injectable contraceptives, and prescription-based hormonal products. Rising awareness of reproductive healthcare, increasing consultations for birth spacing and pregnancy prevention, and improvements in access to specialized gynecological services are expected to support segment growth during the forecast period.

By distribution channel

On the basis of distribution channel, the global contraceptive market is segmented into hospital pharmacies, retail pharmacies & drug stores, online pharmacies, and direct / institutional sales. In 2025, the retail pharmacies & drug stores segment is expected to dominate the global contraceptive market with a market share of 57.45%, owing to their widespread geographic presence, convenient access, and extensive availability of contraceptive products. Retail pharmacies provide consumers with access to oral contraceptive pills, condoms, emergency contraceptives, and other pregnancy prevention products. Established distribution networks, immediate product availability, pharmacist guidance, and growing awareness of reproductive health are further supporting segment dominance.

The online pharmacies segment is expected to experience the fastest CAGR of 6.91% from 2026 to 2033, owing to the increasing adoption of e-commerce healthcare platforms, growing preference for discreet contraceptive purchases, and convenient home delivery services. Online pharmacies enable consumers to compare products, access contraceptive information, and obtain eligible prescription-based products through digital channels. Rising internet penetration, expanding digital healthcare services, and increasing consumer demand for privacy and convenience are expected to support segment growth during the forecast period.

Which Region Holds the Largest Share of the Contraceptive Market?

The North America region dominated the global contraceptive market with the largest revenue share of 39.28% in 2025, supported by established healthcare infrastructure, increasing awareness of reproductive health, and widespread availability of contraceptive products. Strong access to family planning services, retail pharmacies, and prescription-based healthcare, along with growing adoption of modern contraceptive methods, further strengthened regional market demand.

The Middle East and Africa region is expected to be the fastest-growing region in the global contraceptive market, registering a CAGR of 3.95% during 2026–2033. Growth is supported by increasing awareness of family planning, expanding reproductive healthcare initiatives, and improving access to contraceptive products. Government programs and healthcare organizations promoting pregnancy prevention are further contributing to regional market development.

China Contraceptive Market Insight

The China contraceptive Market is driven by rapid infrastructure development, expanding construction and mining activities, and strong demand for heavy machinery across industrial sectors. China’s large manufacturing base and established production capabilities are supporting the adoption of Contraceptive in cranes, excavators, wind turbines, and industrial automation equipment. Increasing investments in renewable energy, particularly wind power installations, are creating additional demand for high-load-capacity and durable bearing solutions. Furthermore, advancements in precision engineering, domestic bearing manufacturing, and equipment modernization are strengthening market development. Growing investments in industrial automation and large-scale infrastructure projects are expected to support market.

Japan Contraceptive Market Insight

The Japan contraceptive Market is driven by the country’s advanced manufacturing sector, increasing industrial automation, and demand for precision-engineered components. Contraceptive are widely used in construction machinery, cranes, robotics, machine tools, mining equipment, and renewable energy systems. Japan’s strong automotive and industrial machinery industries support demand for durable, high-performance bearings that provide rotational accuracy and reliable load handling. Furthermore, investments in wind energy, infrastructure modernization, and automated manufacturing are creating growth opportunities. Technological advancements in bearing materials, lubrication, sealing systems, and condition monitoring are expected to improve operational efficiency and support market development.

Europe Contraceptive Market Insight

The Europe contraceptive market is witnessing steady growth, driven by increasing investments in industrial automation, renewable energy, construction equipment, and advanced manufacturing. Germany remains a key contributor due to its strong automotive, machinery, and engineering industries, while countries such as Spain are supporting demand through infrastructure development and wind energy installations. Contraceptive are widely used in cranes, excavators, wind turbines, material-handling systems, and industrial machinery. Furthermore, advancements in precision engineering, corrosion-resistant materials, and predictive maintenance technologies are supporting product innovation and improving equipment reliability across the region.

North America Contraceptive Market Insight

The North America contraceptive market is driven by increasing awareness of reproductive health, widespread availability of contraceptive products, and established healthcare infrastructure across the U.S. and Canada. Growing demand for oral contraceptive pills, condoms, injectable contraceptives, and intrauterine devices is supporting market development. The region benefits from access to gynecology clinics, retail pharmacies, online pharmacies, and family planning services. Increasing adoption of long-acting reversible contraceptives, expanding digital healthcare platforms, and continued emphasis on pregnancy prevention and reproductive health education are further supporting market growth. However, affordability concerns and variations in healthcare coverage may influence access to contraceptive services.

Which are the Top Companies in Contraceptive Market?

The global contraceptive industry is primarily led by well-established companies, including:

Bayer AG (Germany)
Organon & Co. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Pfizer Inc. (U.S.)
Gedeon Richter Plc. (Hungary)
Viatris Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Lupin (India)
Glenmark Pharmaceuticals (India)
Cipla (India)
Apotex Inc. (Canada)
Insud Pharma, S.L. (Spain)
CooperSurgical, Inc. (U.S.)
Pregna International Limited (India)
SMB Corporation of India (India)
Eurogine (Spain)
OCON Medical Ltd. (Israel)
Shanghai Dahua Pharmaceutical Co., Ltd. (China)
Church & Dwight Co., Inc. (U.S.)
Reckitt (U.K.)
Okamoto Industries, Inc. (Japan)
Sagami Rubber Industries Co., Ltd. (Japan)
Fuji Latex Co., Ltd. (Japan)
Karex Berhad (Malaysia)
Thai Nippon Rubber Industry Public Company Limited (Thailand)
Mayer Laboratories, Inc. (U.S.)
HLL Lifecare Limited (India)
Cupid Limited (India)
TTK Healthcare Limited (India)
Mankind Pharma Limited (India)

What are Latest Developments in Contraceptive Market?

In July 2026, Viatris received U.S. FDA approval for Gwyn Lo, a once-weekly combined hormonal contraceptive patch containing norelgestromin and ethinyl estradiol. The low-dose estrogen patch expands the available reversible contraceptive options and is expected to become commercially available later in 2026.
In April 2026, Duchesnay launched Ringza, a reusable contraceptive vaginal system developed in collaboration with the Population Council. Designed for use across up to 13 menstrual cycles, the slow-release vaginal ring offers a patient-controlled, reversible contraceptive option and expands the range of longer-duration birth control methods available to women.
In June 2025, ASKA Pharmaceutical launched Slinda 28 Tablets, a drospirenone-based oral contraceptive, in Japan after receiving manufacturing and marketing approval in May 2025. The launch expanded the availability of progestin-only oral contraception in the Japanese market.
In February 2026, Contraline and the Population Council entered into a global exclusive licensing agreement for the Nestorone/testosterone (NES/T) male contraceptive gel. Under the agreement, Contraline will lead late-stage development and regulatory engagement, with the goal of advancing this reversible, investigational male contraceptive toward regulatory approval.
In June 2026, Organon completed a global licensing agreement with Sebela Pharmaceuticals for exclusive rights to MIUDELLA, a hormone-free copper intrauterine device approved by the U.S. FDA in February 2025. The agreement strengthens Organon's contraceptive portfolio by adding a long-acting, reversible, non-hormonal pregnancy-prevention option. Commercial availability was anticipated in late 2026.

SKU-56738

Last Updated On: October 26, 2026

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL CONTRACEPTIVE MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL CONTRACEPTIVE MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL CONTRACEPTIVE MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 EPIDEMIOLOGY

4.1 CONTRACEPTIVE PREVALENCE BY REGION AND GENDER

4.2 USAGE RATE AND USER DEMOGRAPHICS

4.3 UNMET NEED FOR FAMILY PLANNING

4.4 ADHERENCE TO CONTRACEPTIVE METHODS

4.5 CONTRACEPTIVE FAILURE AND SWITCHING RATE

4.6 PATIENT TREATMENT SUCCESS RATES

5 REGULATORY FRAMEWORK

5.1 REGULATORY APPROVAL PROCESS

5.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL

5.3 REGULATORY APPROVAL PATHWAYS

5.4 LICENSING AND REGISTRATION

5.5 POST-MARKETING SURVEILLANCE

5.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

6 PIPELINE ANALYSIS

6.1 CLINICAL TRIALS AND PHASE ANALYSIS

6.2 CONTRACEPTIVE DRUG AND DEVICE PIPELINE

6.3 PHASE III CANDIDATES

6.4 PHASE II CANDIDATES

6.5 PHASE I CANDIDATES

6.6 OTHERS (PRE-CLINICAL AND RESEARCH)

7 MARKETED CONTRACEPTIVE PRODUCT ANALYSIS

7.1 CONTRACEPTIVE DRUGS AND DEVICES

7.1.1 BRAND NAME

7.1.2 GENERIC NAME

7.2 THERAPEUTIC INDICATION OR USE

7.3 PHARMACOLOGICAL/MECHANICAL CLASS

7.4 PRIMARY CONTRACEPTIVE INDICATION

7.5 MARKET STATUS

7.6 MEDICATION / DEVICE TYPE

7.7 DOSAGE FORM

7.8 DOSAGES AVAILABILITY / SIZES

7.9 PACKAGING TYPE

7.1 ROUTE/MODE OF ADMINISTRATION

7.11 DOSING FREQUENCY

7.12 PRODUCT INSIGHT

7.13 OVERVIEW OF REGULATORY MILESTONES, SAFETY & EFFICACY DATA, MARKET EXCLUSIVITY

7.13.1 FORECAST MARKET OUTLOOK

7.13.2 CROSS COMPETITION

7.13.3 THERAPEUTIC & TECHNOLOGY PORTFOLIO

7.13.4 CURRENT DEVELOPMENT SCENARIO

8 MARKET ACCESS

8.1 10-YEAR MARKET FORECAST

8.2 CLINICAL TRIAL RECENT UPDATES

8.3 ANNUAL NEW APPROVED PRODUCTS

8.4 MAJOR MANUFACTURERS AND DEALS

8.5 MAJOR PRODUCT UPTAKE

8.6 CURRENT FAMILY PLANNING AND CONTRACEPTIVE PRACTICES

8.7 IMPACT OF UPCOMING INNOVATIONS

9 R & D ANALYSIS

9.1 COMPARATIVE ANALYSIS

9.2 PRODUCT DEVELOPMENT LANDSCAPE

9.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

9.4 TECHNOLOGICAL/TREATMENT ASSESSMENT

9.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

10 MARKET OVERVIEW

10.1 DRIVERS

10.1.1 RISING FOCUS ON PREVENTING UNPLANNED PREGNANCY AND FAMILY PLANNING

10.1.2 GOVERNMENT INITIATIVES AND FUNDING

10.1.3 LONGER LICENSED DURATIONS LIFTING DEMAND FOR LONG-ACTING REVERSIBLE METHODS

10.1.4 PHARMACY AND OVER-THE-COUNTER ACCESS REMOVING THE PRESCRIPTION STEP

10.1.5 NEW PRODUCT APPROVALS WIDENING THE METHOD MIX BEYOND THE PILL AND THE HORMONAL IUD

10.2 RESTRAINTS

10.2.1 CONTRACEPTIVE SIDE EFFECTS

10.2.2 SOCIAL OR RELIGIOUS HESITATION, STIGMA

10.2.3 CONTRACTION OF DONOR FUNDING AFTER THE 2025 U.S. FOREIGN-AID CUTS AND THE CLOSURE OF USAID

10.2.4 GENERIC PRICE EROSION AND REIMBURSEMENT LIMITS ON OFF-PATENT HORMONAL BRANDS

10.3 OPPORTUNITIES

10.3.1 ADVANCES IN NOVEL CONTRACEPTIVE TECHNOLOGIES (LARC, NON-HORMONAL)

10.3.2 GROWTH IN DEVELOPING REGIONS WITH LOW PENETRATION

10.3.3 SELF-INJECTION AND OVER-THE-COUNTER PILLS MOVING CONTRACEPTION OUT OF THE CLINIC

10.3.4 A MALE CONTRACEPTION PIPELINE APPROACHING ITS FIRST PIVOTAL TRIAL

10.4 CHALLENGES

10.4.1 LONG-TERM SAFETY PERCEPTION ISSUES

10.4.2 SHIFT TOWARD LONG-ACTING AND MALE CONTRACEPTIVE OPTIONS

10.4.3 DMPA MENINGIOMA LITIGATION AND LABEL CHANGES ON INJECTABLES

10.4.4 FERTILITY DECLINE SHRINKING THE USER BASE IN AGEING MARKETS

10.5 EMERGING TRENDS IN THE INDUSTRY

10.5.1 TELEHEALTH PLATFORMS AND DIRECT-TO-CONSUMER SITES TAKING OVER THE PILL REFILL

10.5.2 SELF-INJECTABLE DMPA MOVING THE INJECTABLE OUT OF THE CLINIC

10.5.3 NON-HORMONAL AND MALE METHODS ADVANCING THROUGH CLINICAL DEVELOPMENT

10.5.4 WOMEN'S HEALTH PORTFOLIOS CONSOLIDATING INTO FEWER, LARGER OWNERS

10.5.5 DROSPIRENONE BECOMING THE PROGESTIN OF CHOICE IN NEW ORAL CONTRACEPTIVES

10.6 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES

10.7 PORTER'S FIVE FORCES ANALYSIS

10.8 PESTEL ANALYSIS

11 PATENT ANALYSIS

11.1 PATENT NUMBER AND EXPIRY

11.2 COUNTRY LEVEL APPROVAL

11.3 LIST OF PRODUCTS REACHING EXPIRY IN NEXT 3 YEARS

11.4 PRODUCTS PATENTED IN SPECIFIC COUNTRIES

12 COMPANY EVALUATION QUADRANT

13 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2018–2033 (USD MILLION)

13.1 OVERVIEW

13.2 CONTRACEPTIVE DRUGS

13.2.1 ORAL CONTRACEPTIVES

13.2.1.1 COMBINED ORAL CONTRACEPTIVES

13.2.1.1.1 MONOPHASIC PILLS

13.2.1.1.2 21-DAY REGIMEN

13.2.1.1.3 24/4 REGIMEN

13.2.1.1.4 EXTENDED / CONTINUOUS REGIMEN

13.2.1.1.5 BIPHASIC PILLS

13.2.1.1.6 TRIPHASIC PILLS

13.2.1.2 PROGESTIN-ONLY PILLS

13.2.1.2.1 TRADITIONAL PROGESTIN-ONLY PILLS

13.2.1.2.2 DROSPIRENONE-BASED PILLS

13.2.1.3 EMERGENCY CONTRACEPTIVE PILLS

13.2.1.3.1 LEVONORGESTREL-BASED

13.2.1.3.2 SINGLE-DOSE REGIMEN

13.2.1.3.3 SPLIT-DOSE REGIMEN

13.2.1.3.4 ULIPRISTAL ACETATE-BASED

13.2.2 INJECTABLE CONTRACEPTIVES

13.2.2.1 PROGESTIN-ONLY INJECTABLES

13.2.2.1.1 DEPOT MEDROXYPROGESTERONE ACETATE (DMPA)

13.2.2.1.2 INTRAMUSCULAR DMPA

13.2.2.1.3 SUBCUTANEOUS DMPA

13.2.2.1.4 NORETHISTERONE ENANTHATE (NET-EN)

13.2.2.2 COMBINED INJECTABLE CONTRACEPTIVES

13.2.2.2.1 MONTHLY COMBINED INJECTABLES

13.2.3 TRANSDERMAL CONTRACEPTIVE PATCHES

13.2.3.1 COMBINED HORMONAL PATCHES

13.2.3.1.1 ETHINYL ESTRADIOL + NORELGESTROMIN

13.2.3.1.2 ETHINYL ESTRADIOL + LEVONORGESTREL

13.2.4 VAGINAL HORMONAL CONTRACEPTIVES

13.2.4.1 MONTHLY VAGINAL RINGS

13.2.4.1.1 ETONOGESTREL + ETHINYL ESTRADIOL RINGS

13.2.4.2 EXTENDED-USE VAGINAL RINGS

13.2.4.2.1 SEGESTERONE ACETATE + ETHINYL ESTRADIOL RINGS

13.3 CONTRACEPTIVE DEVICES

13.3.1 CONDOMS

13.3.1.1 MALE CONDOMS

13.3.1.1.1 LATEX CONDOMS

13.3.1.1.2 LUBRICATED LATEX CONDOMS

13.3.1.1.3 NON-LUBRICATED LATEX CONDOMS

13.3.1.1.4 NON-LATEX CONDOMS

13.3.1.1.5 POLYURETHANE MALE CONDOMS

13.3.1.1.6 POLYISOPRENE MALE CONDOMS

13.3.1.1.7 OTHER SYNTHETIC MATERIAL CONDOMS

13.3.1.2 FEMALE / INTERNAL CONDOMS

13.3.1.2.1 NITRILE CONDOMS

13.3.1.2.2 POLYURETHANE FEMALE CONDOMS

13.3.1.2.3 OTHER MATERIAL FEMALE CONDOMS

13.3.2 INTRAUTERINE DEVICES (IUDS)

13.3.2.1 COPPER IUDS

13.3.2.1.1 COPPER T-SHAPED IUDS

13.3.2.1.2 CUT 380A

13.3.2.1.3 CUT 375

13.3.2.1.4 OTHER COPPER IUDS

13.3.2.1.5 MULTILOAD / HORSESHOE-TYPE

13.3.2.2 HORMONAL IUDS

13.3.2.2.1 LEVONORGESTREL-RELEASING IUDS

13.3.2.2.2 52 MG LNG-IUDS

13.3.2.2.3 19.5 MG LNG-IUDS

13.3.2.2.4 13.5 MG LNG-IUDS

13.3.3 SUBDERMAL CONTRACEPTIVE IMPLANTS

13.3.3.1 SINGLE-ROD IMPLANTS

13.3.3.1.1 ETONOGESTREL IMPLANTS

13.3.3.2 DOUBLE-ROD IMPLANTS

13.3.3.2.1 LEVONORGESTREL IMPLANTS

13.3.4 OTHER BARRIER CONTRACEPTIVE DEVICES

13.3.4.1 DIAPHRAGMS

13.3.4.1.1 TRADITIONAL DIAPHRAGMS

13.3.4.1.2 ONE-SIZE DIAPHRAGMS

13.3.4.2 CERVICAL CAPS

13.3.4.3 CONTRACEPTIVE SPONGES

13.3.5 FEMALE STERILIZATION DEVICES

13.3.5.1 TUBAL OCCLUSION DEVICES

13.3.5.2 OTHER STERILIZATION DEVICES

13.4 CONTRACEPTIVE SPERMICIDES & ADJUNCT PRODUCTS

13.4.1 SPERMICIDAL GELS

13.4.1.1 NONOXYNOL-9-BASED GELS

13.4.1.2 OTHER SPERMICIDAL GELS

13.4.2 SPERMICIDAL FOAMS

13.4.2.1 AEROSOL FOAMS

13.4.2.2 NON-AEROSOL FOAMS

13.4.3 SPERMICIDAL FILMS

13.4.3.1 VAGINAL CONTRACEPTIVE FILMS

13.4.4 SPERMICIDAL SUPPOSITORIES

13.4.4.1 VAGINAL SUPPOSITORIES

13.4.5 VAGINAL PH MODULATORS

13.4.5.1 LACTIC ACID-BASED

13.4.5.2 CITRIC ACID / POTASSIUM BITARTRATE-BASED

13.4.5.3 OTHER NON-HORMONAL PH MODULATORS

14 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION, 2018–2033 (USD MILLION)

14.1 OVERVIEW

14.2 ESTROGEN + PROGESTIN COMBINATION CONTRACEPTIVES

14.2.1 COMBINED ORAL PILLS

14.2.2 COMBINED TRANSDERMAL PATCHES

14.2.3 COMBINED VAGINAL RINGS

14.2.4 COMBINED INJECTABLES

14.3 PROGESTIN-ONLY CONTRACEPTIVES

14.3.1 PROGESTIN-ONLY ORAL PILLS

14.3.2 PROGESTIN-ONLY INJECTABLES (HORMONAL)

14.3.3 PROGESTIN-ONLY SUBDERMAL IMPLANTS

14.3.4 PROGESTIN-ONLY HORMONAL IUDS

14.4 NON-HORMONAL CONTRACEPTIVES

14.4.1 NON-HORMONAL COPPER IUDS

14.4.2 NON-HORMONAL CONDOMS

14.4.3 NON-HORMONAL DIAPHRAGMS

14.4.4 NON-HORMONAL CERVICAL CAPS

14.4.5 NON-HORMONAL SPERMICIDES

14.4.6 NON-HORMONAL VAGINAL PH MODULATORS

14.4.7 OTHER NON-HORMONAL CONTRACEPTIVES

14.5 OTHER HORMONAL CONTRACEPTIVES

15 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION, 2018–2033 (USD MILLION)

15.1 OVERVIEW

15.2 SHORT-ACTING REVERSIBLE CONTRACEPTIVES

15.2.1 SHORT-ACTING ORAL CONTRACEPTIVE PILLS

15.2.2 SHORT-ACTING CONDOMS

15.2.3 SHORT-ACTING PATCHES

15.2.4 SHORT-ACTING VAGINAL RINGS

15.2.5 SHORT-ACTING SPERMICIDES

15.2.6 OTHER SHORT-ACTING METHODS

15.3 INTERMEDIATE-ACTING CONTRACEPTIVES

15.3.1 INTERMEDIATE-ACTING INJECTABLES

15.4 LONG-ACTING REVERSIBLE CONTRACEPTIVES (LARC)

15.4.1 LARC INTRAUTERINE DEVICES

15.4.1.1 LARC COPPER IUDS

15.4.1.2 LARC HORMONAL IUDS

15.4.2 LARC SUBDERMAL IMPLANTS

15.5 PERMANENT CONTRACEPTION

15.5.1 PERMANENT FEMALE STERILIZATION DEVICES

16 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION, 2018–2033 (USD MILLION)

16.1 OVERVIEW

16.2 ORAL

16.2.1 DAILY ORAL CONTRACEPTIVES

16.2.2 EMERGENCY ORAL CONTRACEPTIVES

16.3 INJECTABLE

16.3.1 INTRAMUSCULAR

16.3.2 SUBCUTANEOUS

16.4 TRANSDERMAL

16.4.1 TRANSDERMAL ROUTE PATCHES

16.5 VAGINAL

16.5.1 VAGINAL ROUTE RINGS

16.5.2 VAGINAL ROUTE SPERMICIDES

16.5.3 VAGINAL ROUTE PH MODULATORS

16.5.4 VAGINAL ROUTE DIAPHRAGMS

16.5.5 VAGINAL ROUTE CERVICAL CAPS

16.5.6 OTHER VAGINAL METHODS

16.6 INTRAUTERINE

16.6.1 INTRAUTERINE COPPER IUDS

16.6.2 INTRAUTERINE HORMONAL IUDS

16.7 SUBDERMAL

16.7.1 SUBDERMAL ROUTE IMPLANTS

16.8 EXTERNAL APPLICATION

16.8.1 EXTERNAL MALE CONDOMS

16.8.2 EXTERNAL FEMALE CONDOMS

16.9 OTHER ROUTES

17 GLOBAL CONTRACEPTIVE MARKET, BY GENDER, 2018–2033 (USD MILLION)

17.1 OVERVIEW

17.2 FEMALE CONTRACEPTIVES

17.2.1 FEMALE ORAL CONTRACEPTIVES

17.2.2 FEMALE INJECTABLES

17.2.3 FEMALE PATCHES

17.2.4 FEMALE VAGINAL RINGS

17.2.5 FEMALE IUDS

17.2.6 FEMALE IMPLANTS

17.2.7 FEMALE DIAPHRAGMS

17.2.8 FEMALE CONDOMS

17.2.9 OTHER FEMALE CONTRACEPTIVES

17.3 MALE CONTRACEPTIVES

17.3.1 MALE CONDOMS (MALE USERS)

18 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS, 2018–2033 (USD MILLION)

18.1 OVERVIEW

18.2 PRESCRIPTION CONTRACEPTIVES

18.2.1 PRESCRIPTION ORAL CONTRACEPTIVES

18.2.2 PRESCRIPTION INJECTABLE CONTRACEPTIVES

18.2.3 PRESCRIPTION PATCHES

18.2.4 PRESCRIPTION VAGINAL RINGS

18.2.5 PRESCRIPTION IUDS

18.2.6 PRESCRIPTION IMPLANTS

18.2.7 OTHER PRESCRIPTION CONTRACEPTIVES

18.3 OVER-THE-COUNTER (OTC) CONTRACEPTIVES

18.3.1 OTC CONDOMS

18.3.2 OTC SPERMICIDES

18.3.3 SELECTED EMERGENCY CONTRACEPTIVE PILLS

18.3.4 OTC VAGINAL PH MODULATORS

18.3.5 OTHER OTC CONTRACEPTIVES

19 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2018–2033 (USD MILLION)

19.1 OVERVIEW

19.2 ADOLESCENTS (10-19 YEARS)

19.3 YOUNG ADULTS (20-29 YEARS)

19.4 ADULTS (30-44 YEARS)

19.5 OLDER REPRODUCTIVE-AGE POPULATION (45-49 YEARS)

20 GLOBAL CONTRACEPTIVE MARKET, BY END USER, 2018–2033 (USD MILLION)

20.1 OVERVIEW

20.2 HOSPITALS

20.2.1 PUBLIC HOSPITALS

20.2.2 PRIVATE HOSPITALS

20.3 GYNECOLOGY & OBSTETRIC CLINICS

20.3.1 GENERAL GYNECOLOGY CLINICS

20.3.2 REPRODUCTIVE HEALTH CLINICS

20.4 FAMILY PLANNING CENTERS

20.4.1 PUBLIC FAMILY PLANNING CENTERS

20.4.2 PRIVATE / NGO-OPERATED FAMILY PLANNING CENTERS

20.5 COMMUNITY HEALTH CENTERS

20.6 INDIVIDUAL / HOME USERS

21 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL, 2018–2033 (USD MILLION)

21.1 OVERVIEW

21.2 HOSPITAL PHARMACIES

21.3 RETAIL PHARMACIES & DRUG STORES

21.4 ONLINE PHARMACIES

21.4.1 PHARMACY WEBSITES

21.4.2 E-COMMERCE PLATFORMS

21.5 DIRECT / INSTITUTIONAL SALES

21.5.1 DIRECT SALES TO HOSPITALS & CLINICS

21.5.2 GOVERNMENT PROCUREMENT

21.5.3 NGO / HUMANITARIAN PROCUREMENT

22 GLOBAL CONTRACEPTIVE MARKET, BY REGION, 2018–2033 (USD MILLION)

22.1 OVERVIEW

22.2 GLOBAL

22.2.1 NORTH AMERICA

22.2.1.1 U.S.

22.2.1.2 CANADA

22.2.1.3 MEXICO

22.2.2 EUROPE

22.2.2.1 GERMANY

22.2.2.2 U.K.

22.2.2.3 ITALY

22.2.2.4 FRANCE

22.2.2.5 SPAIN

22.2.2.6 SWITZERLAND

22.2.2.7 RUSSIA

22.2.2.8 TURKEY

22.2.2.9 BELGIUM

22.2.2.10 NETHERLANDS

22.2.2.11 DENMARK

22.2.2.12 NORWAY

22.2.2.13 FINLAND

22.2.2.14 SWEDEN

22.2.2.15 REST OF EUROPE

22.2.3 ASIA PACIFIC

22.2.3.1 JAPAN

22.2.3.2 CHINA

22.2.3.3 SOUTH KOREA

22.2.3.4 INDIA

22.2.3.5 SINGAPORE

22.2.3.6 THAILAND

22.2.3.7 INDONESIA

22.2.3.8 MALAYSIA

22.2.3.9 PHILIPPINES

22.2.3.10 AUSTRALIA

22.2.3.11 NEW ZEALAND

22.2.3.12 HONG KONG

22.2.3.13 TAIWAN

22.2.3.14 REST OF ASIA-PACIFIC

22.2.4 SOUTH AMERICA

22.2.4.1 ARGENTINA

22.2.4.2 BOLIVIA

22.2.4.3 BRAZIL

22.2.4.4 CHILE

22.2.4.5 COLOMBIA

22.2.4.6 ECUADOR

22.2.4.7 PARAGUAY

22.2.4.8 PERU

22.2.4.9 URUGUAY

22.2.4.10 VENEZUELA

22.2.4.11 REST OF SOUTH AMERICA

22.2.5 MIDDLE EAST AND AFRICA

22.2.5.1 SOUTH AFRICA

22.2.5.2 EGYPT

22.2.5.3 SAUDI ARABIA

22.2.5.4 UNITED ARAB EMIRATES

22.2.5.5 ISRAEL

22.2.5.6 BAHRAIN

22.2.5.7 KUWAIT

22.2.5.8 OMAN

22.2.5.9 QATAR

22.2.5.10 REST OF MIDDLE EAST & AFRICA

23 GLOBAL CONTRACEPTIVE MARKET, COMPANY LANDSCAPE

23.1 COMPANY SHARE ANALYSIS

23.2 MERGERS & ACQUISITIONS

23.3 NEW PRODUCT DEVELOPMENT & APPROVALS

23.4 EXPANSIONS

23.5 REGULATORY CHANGES

23.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

24 GLOBAL CONTRACEPTIVE MARKET, SWOT AND DBMR ANALYSIS

24.1 SWOT ANALYSIS

25 GLOBAL CONTRACEPTIVE MARKET, COMPANY PROFILES

25.1 GLOBAL PHARMACEUTICAL AND WOMEN'S HEALTH COMPANIES

25.1.1 BAYER AG

25.1.1.1 COMPANY OVERVIEW

25.1.1.2 REVENUE ANALYSIS

25.1.1.3 GEOGRAPHIC PRESENCE

25.1.1.4 COLLABORATION

25.1.1.5 PRODUCTION CAPACITY EXPANSION

25.1.1.6 INNOVATIONS

25.1.1.7 EVENTS

25.1.1.8 OTHERS

25.1.1.9 PRODUCT PORTFOLIO

25.1.1.10 RECENT DEVELOPMENTS

25.1.1.11 RECENT NEWS

25.1.2 ORGANON & CO.

25.1.2.1 COMPANY OVERVIEW

25.1.2.2 REVENUE ANALYSIS

25.1.2.3 GEOGRAPHIC PRESENCE

25.1.2.4 MAJOR DEALS

25.1.2.5 M&A

25.1.2.6 COLLABORATION

25.1.2.7 PRODUCT ACQUISITION

25.1.2.8 INNOVATIONS

25.1.2.9 EVENTS

25.1.2.10 OTHERS

25.1.2.11 PRODUCT PORTFOLIO

25.1.2.12 RECENT DEVELOPMENTS

25.1.2.13 RECENT NEWS

25.1.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.

25.1.3.1 COMPANY OVERVIEW

25.1.3.2 REVENUE ANALYSIS

25.1.3.3 GEOGRAPHIC PRESENCE

25.1.3.4 M&A

25.1.3.5 OTHERS

25.1.3.6 PRODUCT PORTFOLIO

25.1.3.7 RECENT DEVELOPMENTS

25.1.3.8 RECENT NEWS

25.1.4 PFIZER INC.

25.1.4.1 COMPANY OVERVIEW

25.1.4.2 REVENUE ANALYSIS

25.1.4.3 GEOGRAPHIC PRESENCE

25.1.4.4 MAJOR DEALS

25.1.4.5 COLLABORATION

25.1.4.6 PRODUCTION CAPACITY EXPANSION

25.1.4.7 OTHERS

25.1.4.8 PRODUCT PORTFOLIO

25.1.4.9 RECENT DEVELOPMENTS

25.1.4.10 RECENT NEWS

25.1.5 GEDEON RICHTER PLC.

25.1.5.1 COMPANY OVERVIEW

25.1.5.2 REVENUE ANALYSIS

25.1.5.3 GEOGRAPHIC PRESENCE

25.1.5.4 MAJOR DEALS

25.1.5.5 M&A

25.1.5.6 COLLABORATION

25.1.5.7 PRODUCT ACQUISITION

25.1.5.8 INNOVATIONS

25.1.5.9 PRODUCT LAUNCHES

25.1.5.10 EVENTS

25.1.5.11 OTHERS

25.1.5.12 PRODUCT PORTFOLIO

25.1.5.13 RECENT DEVELOPMENTS

25.1.5.14 RECENT NEWS

25.1.6 VIATRIS INC.

25.1.6.1 COMPANY OVERVIEW

25.1.6.2 REVENUE ANALYSIS

25.1.6.3 GEOGRAPHIC PRESENCE

25.1.6.4 MAJOR DEALS

25.1.6.5 M&A

25.1.6.6 INNOVATIONS

25.1.6.7 PRODUCT LAUNCHES

25.1.6.8 CONFERENCES

25.1.6.9 OTHERS

25.1.6.10 PRODUCT PORTFOLIO

25.1.6.11 RECENT DEVELOPMENTS

25.1.6.12 RECENT NEWS

25.1.7 SUN PHARMACEUTICAL INDUSTRIES LTD.

25.1.7.1 COMPANY OVERVIEW

25.1.7.2 REVENUE ANALYSIS

25.1.7.3 GEOGRAPHIC PRESENCE

25.1.7.4 MAJOR DEALS

25.1.7.5 M&A

25.1.7.6 INNOVATIONS

25.1.7.7 EVENTS

25.1.7.8 OTHERS

25.1.7.9 PRODUCT PORTFOLIO

25.1.7.10 RECENT DEVELOPMENTS

25.1.7.11 RECENT NEWS

25.1.8 LUPIN

25.1.8.1 COMPANY OVERVIEW

25.1.8.2 REVENUE ANALYSIS

25.1.8.3 GEOGRAPHIC PRESENCE

25.1.8.4 MAJOR DEALS

25.1.8.5 INNOVATIONS

25.1.8.6 PRODUCT LAUNCHES

25.1.8.7 EVENTS

25.1.8.8 OTHERS

25.1.8.9 PRODUCT PORTFOLIO

25.1.8.10 RECENT DEVELOPMENTS

25.1.8.11 RECENT NEWS

25.1.9 GLENMARK PHARMACEUTICALS

25.1.9.1 COMPANY OVERVIEW

25.1.9.2 REVENUE ANALYSIS

25.1.9.3 GEOGRAPHIC PRESENCE

25.1.9.4 MAJOR DEALS

25.1.9.5 M&A

25.1.9.6 INNOVATIONS

25.1.9.7 PRODUCT LAUNCHES

25.1.9.8 EVENTS

25.1.9.9 OTHERS

25.1.9.10 PRODUCT PORTFOLIO

25.1.9.11 RECENT DEVELOPMENTS

25.1.9.12 RECENT NEWS

25.1.10 CIPLA

25.1.10.1 COMPANY OVERVIEW

25.1.10.2 REVENUE ANALYSIS

25.1.10.3 GEOGRAPHIC PRESENCE

25.1.10.4 COLLABORATION

25.1.10.5 INNOVATIONS

25.1.10.6 EVENTS

25.1.10.7 OTHERS

25.1.10.8 PRODUCT PORTFOLIO

25.1.10.9 RECENT DEVELOPMENTS

25.1.10.10 RECENT NEWS

25.1.11 APOTEX INC.

25.1.11.1 COMPANY OVERVIEW

25.1.11.2 REVENUE ANALYSIS

25.1.11.3 GEOGRAPHIC PRESENCE

25.1.11.4 MAJOR DEALS

25.1.11.5 M&A

25.1.11.6 INNOVATIONS

25.1.11.7 EVENTS

25.1.11.8 OTHERS

25.1.11.9 PRODUCT PORTFOLIO

25.1.11.10 RECENT DEVELOPMENTS

25.1.11.11 RECENT NEWS

25.1.12 INSUD PHARMA, S.L.

25.1.12.1 COMPANY OVERVIEW

25.1.12.2 REVENUE ANALYSIS

25.1.12.3 GEOGRAPHIC PRESENCE

25.1.12.4 MAJOR DEALS

25.1.12.5 M&A

25.1.12.6 COLLABORATION

25.1.12.7 PRODUCT ACQUISITION

25.1.12.8 PRODUCTION CAPACITY EXPANSION

25.1.12.9 INNOVATIONS

25.1.12.10 PRODUCT LAUNCHES

25.1.12.11 OTHERS

25.1.12.12 PRODUCT PORTFOLIO

25.1.12.13 RECENT DEVELOPMENTS

25.1.12.14 RECENT NEWS

25.1.13 COOPERSURGICAL, INC.

25.1.13.1 COMPANY OVERVIEW

25.1.13.2 REVENUE ANALYSIS

25.1.13.3 GEOGRAPHIC PRESENCE

25.1.13.4 MAJOR DEALS

25.1.13.5 M&A

25.1.13.6 PRODUCT ACQUISITION

25.1.13.7 PRODUCTION CAPACITY EXPANSION

25.1.13.8 INNOVATIONS

25.1.13.9 PRODUCT LAUNCHES

25.1.13.10 EVENTS

25.1.13.11 CONFERENCES

25.1.13.12 WEBINARS

25.1.13.13 OTHERS

25.1.13.14 PRODUCT PORTFOLIO

25.1.13.15 RECENT DEVELOPMENTS

25.1.13.16 RECENT NEWS

25.1.14 MANKIND

25.1.14.1 COMPANY OVERVIEW

25.1.14.2 REVENUE ANALYSIS

25.1.14.3 GEOGRAPHIC PRESENCE

25.1.14.4 MAJOR DEALS

25.1.14.5 M&A

25.1.14.6 COLLABORATION

25.1.14.7 PRODUCTION CAPACITY EXPANSION

25.1.14.8 INNOVATIONS

25.1.14.9 PRODUCT LAUNCHES

25.1.14.10 EVENTS

25.1.14.11 OTHERS

25.1.14.12 PRODUCT PORTFOLIO

25.1.14.13 RECENT DEVELOPMENTS

25.1.14.14 RECENT NEWS

25.2 CONDOM AND BARRIER-METHOD MANUFACTURERS

25.2.1 CHURCH & DWIGHT CO., INC.

25.2.1.1 COMPANY OVERVIEW

25.2.1.2 REVENUE ANALYSIS

25.2.1.3 GEOGRAPHIC PRESENCE

25.2.1.4 M&A

25.2.1.5 INNOVATIONS

25.2.1.6 PRODUCT LAUNCHES

25.2.1.7 OTHERS

25.2.1.8 PRODUCT PORTFOLIO

25.2.1.9 RECENT DEVELOPMENTS

25.2.1.10 RECENT NEWS

25.2.2 RECKITT

25.2.2.1 COMPANY OVERVIEW

25.2.2.2 REVENUE ANALYSIS

25.2.2.3 GEOGRAPHIC PRESENCE

25.2.2.4 MAJOR DEALS

25.2.2.5 M&A

25.2.2.6 INNOVATIONS

25.2.2.7 PRODUCT LAUNCHES

25.2.2.8 EVENTS

25.2.2.9 OTHERS

25.2.2.10 PRODUCT PORTFOLIO

25.2.2.11 RECENT DEVELOPMENTS

25.2.2.12 RECENT NEWS

25.2.3 OKAMOTO INDUSTRIES, INC.

25.2.3.1 COMPANY OVERVIEW

25.2.3.2 REVENUE ANALYSIS

25.2.3.3 GEOGRAPHIC PRESENCE

25.2.3.4 PRODUCTION CAPACITY EXPANSION

25.2.3.5 INNOVATIONS

25.2.3.6 PRODUCT LAUNCHES

25.2.3.7 OTHERS

25.2.3.8 PRODUCT PORTFOLIO

25.2.3.9 RECENT DEVELOPMENTS

25.2.3.10 RECENT NEWS

25.2.4 SAGAMI RUBBER INDUSTRIES CO., LTD.

25.2.4.1 COMPANY OVERVIEW

25.2.4.2 REVENUE ANALYSIS

25.2.4.3 GEOGRAPHIC PRESENCE

25.2.4.4 COLLABORATION

25.2.4.5 PRODUCTION CAPACITY EXPANSION

25.2.4.6 INNOVATIONS

25.2.4.7 PRODUCT LAUNCHES

25.2.4.8 EVENTS

25.2.4.9 OTHERS

25.2.4.10 PRODUCT PORTFOLIO

25.2.4.11 RECENT DEVELOPMENTS

25.2.4.12 RECENT NEWS

25.2.5 FUJI LATEX CO., LTD.

25.2.5.1 COMPANY OVERVIEW

25.2.5.2 REVENUE ANALYSIS

25.2.5.3 GEOGRAPHIC PRESENCE

25.2.5.4 COLLABORATION

25.2.5.5 PRODUCTION CAPACITY EXPANSION

25.2.5.6 INNOVATIONS

25.2.5.7 PRODUCT LAUNCHES

25.2.5.8 EVENTS

25.2.5.9 OTHERS

25.2.5.10 PRODUCT PORTFOLIO

25.2.5.11 RECENT DEVELOPMENTS

25.2.5.12 RECENT NEWS

25.2.6 KAREX BERHAD

25.2.6.1 COMPANY OVERVIEW

25.2.6.2 REVENUE ANALYSIS

25.2.6.3 GEOGRAPHIC PRESENCE

25.2.6.4 COLLABORATION

25.2.6.5 PRODUCTION CAPACITY EXPANSION

25.2.6.6 INNOVATIONS

25.2.6.7 PRODUCT LAUNCHES

25.2.6.8 EVENTS

25.2.6.9 OTHERS

25.2.6.10 PRODUCT PORTFOLIO

25.2.6.11 RECENT DEVELOPMENTS

25.2.6.12 RECENT NEWS

25.2.7 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED

25.2.7.1 COMPANY OVERVIEW

25.2.7.2 REVENUE ANALYSIS

25.2.7.3 GEOGRAPHIC PRESENCE

25.2.7.4 MAJOR DEALS

25.2.7.5 COLLABORATION

25.2.7.6 PRODUCT ACQUISITION

25.2.7.7 PRODUCTION CAPACITY EXPANSION

25.2.7.8 INNOVATIONS

25.2.7.9 PRODUCT LAUNCHES

25.2.7.10 EVENTS

25.2.7.11 OTHERS

25.2.7.12 PRODUCT PORTFOLIO

25.2.7.13 RECENT DEVELOPMENTS

25.2.7.14 RECENT NEWS

25.2.8 MAYER LABORATORIES, INC.

25.2.8.1 COMPANY OVERVIEW

25.2.8.2 GEOGRAPHIC PRESENCE

25.2.8.3 COLLABORATION

25.2.8.4 INNOVATIONS

25.2.8.5 OTHERS

25.2.8.6 PRODUCT PORTFOLIO

25.2.8.7 RECENT DEVELOPMENTS

25.2.8.8 RECENT NEWS

25.2.9 CUPID

25.2.9.1 COMPANY OVERVIEW

25.2.9.2 REVENUE ANALYSIS

25.2.9.3 GEOGRAPHIC PRESENCE

25.2.9.4 MAJOR DEALS

25.2.9.5 M&A

25.2.9.6 COLLABORATION

25.2.9.7 PRODUCTION CAPACITY EXPANSION

25.2.9.8 INNOVATIONS

25.2.9.9 PRODUCT LAUNCHES

25.2.9.10 OTHERS

25.2.9.11 PRODUCT PORTFOLIO

25.2.9.12 RECENT DEVELOPMENTS

25.2.9.13 RECENT NEWS

25.2.10 TTK

25.2.10.1 COMPANY OVERVIEW

25.2.10.2 REVENUE ANALYSIS

25.2.10.3 GEOGRAPHIC PRESENCE

25.2.10.4 MAJOR DEALS

25.2.10.5 COLLABORATION

25.2.10.6 PRODUCTION CAPACITY EXPANSION

25.2.10.7 JOINT VENTURES

25.2.10.8 INNOVATIONS

25.2.10.9 PRODUCT LAUNCHES

25.2.10.10 OTHERS

25.2.10.11 PRODUCT PORTFOLIO

25.2.10.12 RECENT DEVELOPMENTS

25.2.10.13 RECENT NEWS

25.3 DEVICE AND GENERIC MAKERS SERVING PUBLIC-SECTOR PROGRAMMES

25.3.1 PREGNA INTERNATIONAL LIMITED

25.3.1.1 COMPANY OVERVIEW

25.3.1.2 GEOGRAPHIC PRESENCE

25.3.1.3 MAJOR DEALS

25.3.1.4 INNOVATIONS

25.3.1.5 PRODUCT LAUNCHES

25.3.1.6 OTHERS

25.3.1.7 PRODUCT PORTFOLIO

25.3.1.8 RECENT DEVELOPMENTS

25.3.1.9 RECENT NEWS

25.3.2 SMB CORPORATION OF INDIA

25.3.2.1 COMPANY OVERVIEW

25.3.2.2 GEOGRAPHIC PRESENCE

25.3.2.3 PRODUCTION CAPACITY EXPANSION

25.3.2.4 INNOVATIONS

25.3.2.5 PRODUCT LAUNCHES

25.3.2.6 EVENTS

25.3.2.7 CONFERENCES

25.3.2.8 OTHERS

25.3.2.9 PRODUCT PORTFOLIO

25.3.2.10 RECENT DEVELOPMENTS

25.3.2.11 RECENT NEWS

25.3.3 EUROGINE

25.3.3.1 COMPANY OVERVIEW

25.3.3.2 REVENUE ANALYSIS

25.3.3.3 GEOGRAPHIC PRESENCE

25.3.3.4 COLLABORATION

25.3.3.5 PRODUCTION CAPACITY EXPANSION

25.3.3.6 INNOVATIONS

25.3.3.7 EVENTS

25.3.3.8 SYMPOSIUMS

25.3.3.9 OTHERS

25.3.3.10 PRODUCT PORTFOLIO

25.3.3.11 RECENT DEVELOPMENTS

25.3.3.12 RECENT NEWS

25.3.4 OCON MEDICAL LTD.

25.3.4.1 COMPANY OVERVIEW

25.3.4.2 REVENUE ANALYSIS

25.3.4.3 GEOGRAPHIC PRESENCE

25.3.4.4 MAJOR DEALS

25.3.4.5 COLLABORATION

25.3.4.6 PRODUCTION CAPACITY EXPANSION

25.3.4.7 INNOVATIONS

25.3.4.8 EVENTS

25.3.4.9 OTHERS

25.3.4.10 PRODUCT PORTFOLIO

25.3.4.11 RECENT DEVELOPMENTS

25.3.4.12 RECENT NEWS

25.3.5 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.

25.3.5.1 COMPANY OVERVIEW

25.3.5.2 REVENUE ANALYSIS

25.3.5.3 GEOGRAPHIC PRESENCE

25.3.5.4 COLLABORATION

25.3.5.5 PRODUCTION CAPACITY EXPANSION

25.3.5.6 INNOVATIONS

25.3.5.7 EVENTS

25.3.5.8 CONFERENCES

25.3.5.9 OTHERS

25.3.5.10 PRODUCT PORTFOLIO

25.3.5.11 RECENT DEVELOPMENTS

25.3.5.12 RECENT NEWS

25.3.6 HLL LIFECARE LIMITED

25.3.6.1 COMPANY OVERVIEW

25.3.6.2 REVENUE ANALYSIS

25.3.6.3 GEOGRAPHIC PRESENCE

25.3.6.4 MAJOR DEALS

25.3.6.5 COLLABORATION

25.3.6.6 PRODUCTION CAPACITY EXPANSION

25.3.6.7 JOINT VENTURES

25.3.6.8 INNOVATIONS

25.3.6.9 PRODUCT LAUNCHES

25.3.6.10 EVENTS

25.3.6.11 OTHERS

25.3.6.12 PRODUCT PORTFOLIO

25.3.6.13 RECENT DEVELOPMENTS

25.3.6.14 RECENT NEWS

26 RELATED REPORTS

27 CONCLUSION

28 QUESTIONNAIRE

List of Table

TABLE 1 GLOBAL CONTRACEPTIVE MARKET: CHALLENGE MATRIX

TABLE 2 GLOBAL CONTRACEPTIVE MARKET: RESEARCH SNAPSHOT

TABLE 3 WOMEN USING CONTRACEPTION BY REGION, 2015, 2025 AND 2030 (MILLION)

TABLE 4 CURRENT CONTRACEPTIVE USE AMONG WOMEN AGED 15-49 IN THE UNITED STATES, BY METHOD, FROM THE LATEST NSFG SURVEY

TABLE 5 NEED FOR AND USE OF FAMILY PLANNING, WORLD AND INDIA

TABLE 6 DISCONTINUATION, SWITCHING AND ABANDONMENT OF REVERSIBLE METHODS IN 61 DHS COUNTRIES

TABLE 7 PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY IN THE FIRST YEAR OF USE, BY METHOD

TABLE 8 EASE OF REGULATORY APPROVAL FOR CONTRACEPTIVES, BY GEOGRAPHY

TABLE 9 APPROVAL ROUTES BY CONTRACEPTIVE TYPE

TABLE 10 CONTRACEPTIVE PIPELINE, 22 CANDIDATES LISTED, BY PHASE AND TYPE

TABLE 11 GLOBAL CONTRACEPTIVE PIPELINE, CANDIDATES BY HIGHEST PHASE REACHED

TABLE 12 PHASE III CONTRACEPTIVE CANDIDATES

TABLE 13 PHASE II CONTRACEPTIVE CANDIDATES

TABLE 14 PHASE I CONTRACEPTIVE CANDIDATES

TABLE 15 PRE-CLINICAL AND RESEARCH-STAGE CONTRACEPTIVE CANDIDATES

TABLE 16 LEADING MARKETED CONTRACEPTIVE DRUGS AND DEVICES

TABLE 17 DOSING INTERVAL BY METHOD

TABLE 18 REGULATORY MILESTONES FOR LEADING CONTRACEPTIVES

TABLE 19 GLOBAL CONTRACEPTIVE MARKET BY SEGMENT, USD MILLION, 2025 AND 2033

TABLE 20 SELECTED CONTRACEPTIVE CLINICAL PROGRAMMES AND THEIR LATEST STATUS

TABLE 21 RECENT CONTRACEPTIVE APPROVALS AND LABEL CHANGES

TABLE 22 MAJOR CONTRACEPTIVE ACQUISITIONS AND LICENCES SINCE 2024

TABLE 23 NUMBER OF WOMEN USING EACH CONTRACEPTIVE METHOD WORLDWIDE, 2020

TABLE 24 COMPARATIVE ANALYSIS OF CONTRACEPTIVE DEVELOPMENT APPROACHES

TABLE 25 CONTRACEPTIVE REGULATORY MILESTONES SINCE 2018

TABLE 26 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS IN CONTRACEPTION

TABLE 27 GLOBAL CONTRACEPTIVE MARKET: DRIVERS IMPACT ANALYSIS

TABLE 28 GLOBAL CONTRACEPTIVE MARKET: RESTRAINTS IMPACT ANALYSIS

TABLE 29 GLOBAL CONTRACEPTIVE MARKET: OPPORTUNITIES IMPACT ANALYSIS

TABLE 30 GLOBAL CONTRACEPTIVE MARKET: CHALLENGES IMPACT ANALYSIS

TABLE 31 GLOBAL CONTRACEPTIVE MARKET: TRENDS IMPACT ANALYSIS

TABLE 32 GLOBAL CONTRACEPTIVE MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

TABLE 33 GLOBAL CONTRACEPTIVE MARKET: PESTEL ANALYSIS

TABLE 34 FDA ORANGE BOOK PATENTS LISTED FOR BRANDED CONTRACEPTIVES

TABLE 35 ORANGE BOOK PATENTS AND EXCLUSIVITIES EXPIRING 2026 TO 2029

TABLE 36 COMPANY EVALUATION QUADRANT, GLOBAL CONTRACEPTIVE MARKET

TABLE 37 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 38 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 39 CONTRACEPTIVE DRUGS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 40 CONTRACEPTIVE DRUGS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 41 ORAL CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 42 ORAL CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 43 COMBINED ORAL CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 44 COMBINED ORAL CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 45 MONOPHASIC PILLS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 46 MONOPHASIC PILLS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 47 PROGESTIN-ONLY PILLS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 48 PROGESTIN-ONLY PILLS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 49 EMERGENCY CONTRACEPTIVE PILLS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 50 EMERGENCY CONTRACEPTIVE PILLS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 51 LEVONORGESTREL-BASED, BY TYPE, 2018-2025 (USD MILLION)

TABLE 52 LEVONORGESTREL-BASED, BY TYPE, 2026-2033 (USD MILLION)

TABLE 53 INJECTABLE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 54 INJECTABLE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 55 PROGESTIN-ONLY INJECTABLES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 56 PROGESTIN-ONLY INJECTABLES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 57 DEPOT MEDROXYPROGESTERONE ACETATE (DMPA), BY TYPE, 2018-2025 (USD MILLION)

TABLE 58 DEPOT MEDROXYPROGESTERONE ACETATE (DMPA), BY TYPE, 2026-2033 (USD MILLION)

TABLE 59 COMBINED INJECTABLE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 60 COMBINED INJECTABLE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 61 TRANSDERMAL CONTRACEPTIVE PATCHES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 62 TRANSDERMAL CONTRACEPTIVE PATCHES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 63 COMBINED HORMONAL PATCHES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 64 COMBINED HORMONAL PATCHES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 65 VAGINAL HORMONAL CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 66 VAGINAL HORMONAL CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 67 MONTHLY VAGINAL RINGS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 68 MONTHLY VAGINAL RINGS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 69 EXTENDED-USE VAGINAL RINGS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 70 EXTENDED-USE VAGINAL RINGS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 71 CONTRACEPTIVE DEVICES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 72 CONTRACEPTIVE DEVICES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 73 CONDOMS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 74 CONDOMS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 75 MALE CONDOMS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 76 MALE CONDOMS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 77 LATEX CONDOMS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 78 LATEX CONDOMS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 79 NON-LATEX CONDOMS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 80 NON-LATEX CONDOMS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 81 FEMALE / INTERNAL CONDOMS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 82 FEMALE / INTERNAL CONDOMS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 83 INTRAUTERINE DEVICES (IUDS), BY TYPE, 2018-2025 (USD MILLION)

TABLE 84 INTRAUTERINE DEVICES (IUDS), BY TYPE, 2026-2033 (USD MILLION)

TABLE 85 COPPER IUDS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 86 COPPER IUDS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 87 COPPER T-SHAPED IUDS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 88 COPPER T-SHAPED IUDS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 89 HORMONAL IUDS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 90 HORMONAL IUDS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 91 LEVONORGESTREL-RELEASING IUDS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 92 LEVONORGESTREL-RELEASING IUDS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 93 SUBDERMAL CONTRACEPTIVE IMPLANTS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 94 SUBDERMAL CONTRACEPTIVE IMPLANTS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 95 SINGLE-ROD IMPLANTS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 96 SINGLE-ROD IMPLANTS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 97 DOUBLE-ROD IMPLANTS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 98 DOUBLE-ROD IMPLANTS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 99 OTHER BARRIER CONTRACEPTIVE DEVICES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 100 OTHER BARRIER CONTRACEPTIVE DEVICES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 101 DIAPHRAGMS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 102 DIAPHRAGMS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 103 FEMALE STERILIZATION DEVICES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 104 FEMALE STERILIZATION DEVICES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 105 CONTRACEPTIVE SPERMICIDES & ADJUNCT PRODUCTS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 106 CONTRACEPTIVE SPERMICIDES & ADJUNCT PRODUCTS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 107 SPERMICIDAL GELS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 108 SPERMICIDAL GELS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 109 SPERMICIDAL FOAMS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 110 SPERMICIDAL FOAMS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 111 SPERMICIDAL FILMS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 112 SPERMICIDAL FILMS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 113 SPERMICIDAL SUPPOSITORIES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 114 SPERMICIDAL SUPPOSITORIES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 115 VAGINAL PH MODULATORS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 116 VAGINAL PH MODULATORS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 117 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 118 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 119 ESTROGEN + PROGESTIN COMBINATION CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 120 ESTROGEN + PROGESTIN COMBINATION CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 121 PROGESTIN-ONLY CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 122 PROGESTIN-ONLY CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 123 NON-HORMONAL CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 124 NON-HORMONAL CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 125 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 126 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 127 SHORT-ACTING REVERSIBLE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 128 SHORT-ACTING REVERSIBLE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 129 INTERMEDIATE-ACTING CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 130 INTERMEDIATE-ACTING CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 131 LONG-ACTING REVERSIBLE CONTRACEPTIVES (LARC), BY TYPE, 2018-2025 (USD MILLION)

TABLE 132 LONG-ACTING REVERSIBLE CONTRACEPTIVES (LARC), BY TYPE, 2026-2033 (USD MILLION)

TABLE 133 LARC INTRAUTERINE DEVICES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 134 LARC INTRAUTERINE DEVICES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 135 PERMANENT CONTRACEPTION, BY TYPE, 2018-2025 (USD MILLION)

TABLE 136 PERMANENT CONTRACEPTION, BY TYPE, 2026-2033 (USD MILLION)

TABLE 137 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 138 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 139 ORAL, BY TYPE, 2018-2025 (USD MILLION)

TABLE 140 ORAL, BY TYPE, 2026-2033 (USD MILLION)

TABLE 141 INJECTABLE, BY TYPE, 2018-2025 (USD MILLION)

TABLE 142 INJECTABLE, BY TYPE, 2026-2033 (USD MILLION)

TABLE 143 TRANSDERMAL, BY TYPE, 2018-2025 (USD MILLION)

TABLE 144 TRANSDERMAL, BY TYPE, 2026-2033 (USD MILLION)

TABLE 145 VAGINAL, BY TYPE, 2018-2025 (USD MILLION)

TABLE 146 VAGINAL, BY TYPE, 2026-2033 (USD MILLION)

TABLE 147 INTRAUTERINE, BY TYPE, 2018-2025 (USD MILLION)

TABLE 148 INTRAUTERINE, BY TYPE, 2026-2033 (USD MILLION)

TABLE 149 SUBDERMAL, BY TYPE, 2018-2025 (USD MILLION)

TABLE 150 SUBDERMAL, BY TYPE, 2026-2033 (USD MILLION)

TABLE 151 EXTERNAL APPLICATION, BY TYPE, 2018-2025 (USD MILLION)

TABLE 152 EXTERNAL APPLICATION, BY TYPE, 2026-2033 (USD MILLION)

TABLE 153 GLOBAL CONTRACEPTIVE MARKET, BY GENDER, 2018-2025 (USD MILLION)

TABLE 154 GLOBAL CONTRACEPTIVE MARKET, BY GENDER, 2026-2033 (USD MILLION)

TABLE 155 FEMALE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 156 FEMALE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 157 MALE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 158 MALE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 159 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 160 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 161 PRESCRIPTION CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 162 PRESCRIPTION CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 163 OVER-THE-COUNTER (OTC) CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 164 OVER-THE-COUNTER (OTC) CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 165 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 166 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 167 GLOBAL CONTRACEPTIVE MARKET, BY END USER, 2018-2025 (USD MILLION)

TABLE 168 GLOBAL CONTRACEPTIVE MARKET, BY END USER, 2026-2033 (USD MILLION)

TABLE 169 HOSPITALS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 170 HOSPITALS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 171 GYNECOLOGY & OBSTETRIC CLINICS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 172 GYNECOLOGY & OBSTETRIC CLINICS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 173 FAMILY PLANNING CENTERS, BY TYPE, 2018-2025 (USD MILLION)

TABLE 174 FAMILY PLANNING CENTERS, BY TYPE, 2026-2033 (USD MILLION)

TABLE 175 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 176 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 177 ONLINE PHARMACIES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 178 ONLINE PHARMACIES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 179 DIRECT / INSTITUTIONAL SALES, BY TYPE, 2018-2025 (USD MILLION)

TABLE 180 DIRECT / INSTITUTIONAL SALES, BY TYPE, 2026-2033 (USD MILLION)

TABLE 181 GLOBAL CONTRACEPTIVE MARKET, BY REGION, 2018-2025 (USD MILLION)

TABLE 182 GLOBAL CONTRACEPTIVE MARKET, BY REGION, 2026-2033 (USD MILLION)

TABLE 183 NORTH AMERICA, BY COUNTRY, 2018-2025 (USD MILLION)

TABLE 184 NORTH AMERICA, BY COUNTRY, 2026-2033 (USD MILLION)

TABLE 185 NORTH AMERICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 186 NORTH AMERICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 187 NORTH AMERICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 188 NORTH AMERICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 189 NORTH AMERICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 190 NORTH AMERICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 191 NORTH AMERICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 192 NORTH AMERICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 193 NORTH AMERICA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 194 NORTH AMERICA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 195 NORTH AMERICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 196 NORTH AMERICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 197 NORTH AMERICA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 198 NORTH AMERICA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 199 NORTH AMERICA, BY END USER, 2018-2025 (USD MILLION)

TABLE 200 NORTH AMERICA, BY END USER, 2026-2033 (USD MILLION)

TABLE 201 NORTH AMERICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 202 NORTH AMERICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 203 U.S., BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 204 U.S., BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 205 U.S., BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 206 U.S., BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 207 U.S., BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 208 U.S., BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 209 U.S., BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 210 U.S., BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 211 U.S., BY GENDER, 2018-2025 (USD MILLION)

TABLE 212 U.S., BY GENDER, 2026-2033 (USD MILLION)

TABLE 213 U.S., BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 214 U.S., BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 215 U.S., BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 216 U.S., BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 217 U.S., BY END USER, 2018-2025 (USD MILLION)

TABLE 218 U.S., BY END USER, 2026-2033 (USD MILLION)

TABLE 219 U.S., BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 220 U.S., BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 221 CANADA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 222 CANADA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 223 CANADA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 224 CANADA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 225 CANADA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 226 CANADA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 227 CANADA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 228 CANADA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 229 CANADA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 230 CANADA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 231 CANADA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 232 CANADA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 233 CANADA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 234 CANADA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 235 CANADA, BY END USER, 2018-2025 (USD MILLION)

TABLE 236 CANADA, BY END USER, 2026-2033 (USD MILLION)

TABLE 237 CANADA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 238 CANADA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 239 MEXICO, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 240 MEXICO, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 241 MEXICO, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 242 MEXICO, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 243 MEXICO, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 244 MEXICO, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 245 MEXICO, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 246 MEXICO, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 247 MEXICO, BY GENDER, 2018-2025 (USD MILLION)

TABLE 248 MEXICO, BY GENDER, 2026-2033 (USD MILLION)

TABLE 249 MEXICO, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 250 MEXICO, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 251 MEXICO, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 252 MEXICO, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 253 MEXICO, BY END USER, 2018-2025 (USD MILLION)

TABLE 254 MEXICO, BY END USER, 2026-2033 (USD MILLION)

TABLE 255 MEXICO, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 256 MEXICO, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 257 EUROPE, BY COUNTRY, 2018-2025 (USD MILLION)

TABLE 258 EUROPE, BY COUNTRY, 2026-2033 (USD MILLION)

TABLE 259 EUROPE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 260 EUROPE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 261 EUROPE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 262 EUROPE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 263 EUROPE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 264 EUROPE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 265 EUROPE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 266 EUROPE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 267 EUROPE, BY GENDER, 2018-2025 (USD MILLION)

TABLE 268 EUROPE, BY GENDER, 2026-2033 (USD MILLION)

TABLE 269 EUROPE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 270 EUROPE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 271 EUROPE, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 272 EUROPE, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 273 EUROPE, BY END USER, 2018-2025 (USD MILLION)

TABLE 274 EUROPE, BY END USER, 2026-2033 (USD MILLION)

TABLE 275 EUROPE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 276 EUROPE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 277 GERMANY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 278 GERMANY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 279 GERMANY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 280 GERMANY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 281 GERMANY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 282 GERMANY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 283 GERMANY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 284 GERMANY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 285 GERMANY, BY GENDER, 2018-2025 (USD MILLION)

TABLE 286 GERMANY, BY GENDER, 2026-2033 (USD MILLION)

TABLE 287 GERMANY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 288 GERMANY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 289 GERMANY, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 290 GERMANY, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 291 GERMANY, BY END USER, 2018-2025 (USD MILLION)

TABLE 292 GERMANY, BY END USER, 2026-2033 (USD MILLION)

TABLE 293 GERMANY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 294 GERMANY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 295 U.K., BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 296 U.K., BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 297 U.K., BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 298 U.K., BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 299 U.K., BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 300 U.K., BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 301 U.K., BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 302 U.K., BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 303 U.K., BY GENDER, 2018-2025 (USD MILLION)

TABLE 304 U.K., BY GENDER, 2026-2033 (USD MILLION)

TABLE 305 U.K., BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 306 U.K., BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 307 U.K., BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 308 U.K., BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 309 U.K., BY END USER, 2018-2025 (USD MILLION)

TABLE 310 U.K., BY END USER, 2026-2033 (USD MILLION)

TABLE 311 U.K., BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 312 U.K., BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 313 ITALY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 314 ITALY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 315 ITALY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 316 ITALY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 317 ITALY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 318 ITALY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 319 ITALY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 320 ITALY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 321 ITALY, BY GENDER, 2018-2025 (USD MILLION)

TABLE 322 ITALY, BY GENDER, 2026-2033 (USD MILLION)

TABLE 323 ITALY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 324 ITALY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 325 ITALY, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 326 ITALY, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 327 ITALY, BY END USER, 2018-2025 (USD MILLION)

TABLE 328 ITALY, BY END USER, 2026-2033 (USD MILLION)

TABLE 329 ITALY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 330 ITALY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 331 FRANCE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 332 FRANCE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 333 FRANCE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 334 FRANCE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 335 FRANCE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 336 FRANCE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 337 FRANCE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 338 FRANCE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 339 FRANCE, BY GENDER, 2018-2025 (USD MILLION)

TABLE 340 FRANCE, BY GENDER, 2026-2033 (USD MILLION)

TABLE 341 FRANCE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 342 FRANCE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 343 FRANCE, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 344 FRANCE, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 345 FRANCE, BY END USER, 2018-2025 (USD MILLION)

TABLE 346 FRANCE, BY END USER, 2026-2033 (USD MILLION)

TABLE 347 FRANCE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 348 FRANCE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 349 SPAIN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 350 SPAIN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 351 SPAIN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 352 SPAIN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 353 SPAIN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 354 SPAIN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 355 SPAIN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 356 SPAIN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 357 SPAIN, BY GENDER, 2018-2025 (USD MILLION)

TABLE 358 SPAIN, BY GENDER, 2026-2033 (USD MILLION)

TABLE 359 SPAIN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 360 SPAIN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 361 SPAIN, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 362 SPAIN, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 363 SPAIN, BY END USER, 2018-2025 (USD MILLION)

TABLE 364 SPAIN, BY END USER, 2026-2033 (USD MILLION)

TABLE 365 SPAIN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 366 SPAIN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 367 SWITZERLAND, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 368 SWITZERLAND, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 369 SWITZERLAND, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 370 SWITZERLAND, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 371 SWITZERLAND, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 372 SWITZERLAND, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 373 SWITZERLAND, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 374 SWITZERLAND, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 375 SWITZERLAND, BY GENDER, 2018-2025 (USD MILLION)

TABLE 376 SWITZERLAND, BY GENDER, 2026-2033 (USD MILLION)

TABLE 377 SWITZERLAND, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 378 SWITZERLAND, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 379 SWITZERLAND, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 380 SWITZERLAND, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 381 SWITZERLAND, BY END USER, 2018-2025 (USD MILLION)

TABLE 382 SWITZERLAND, BY END USER, 2026-2033 (USD MILLION)

TABLE 383 SWITZERLAND, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 384 SWITZERLAND, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 385 RUSSIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 386 RUSSIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 387 RUSSIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 388 RUSSIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 389 RUSSIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 390 RUSSIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 391 RUSSIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 392 RUSSIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 393 RUSSIA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 394 RUSSIA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 395 RUSSIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 396 RUSSIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 397 RUSSIA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 398 RUSSIA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 399 RUSSIA, BY END USER, 2018-2025 (USD MILLION)

TABLE 400 RUSSIA, BY END USER, 2026-2033 (USD MILLION)

TABLE 401 RUSSIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 402 RUSSIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 403 TURKEY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 404 TURKEY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 405 TURKEY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 406 TURKEY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 407 TURKEY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 408 TURKEY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 409 TURKEY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 410 TURKEY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 411 TURKEY, BY GENDER, 2018-2025 (USD MILLION)

TABLE 412 TURKEY, BY GENDER, 2026-2033 (USD MILLION)

TABLE 413 TURKEY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 414 TURKEY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 415 TURKEY, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 416 TURKEY, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 417 TURKEY, BY END USER, 2018-2025 (USD MILLION)

TABLE 418 TURKEY, BY END USER, 2026-2033 (USD MILLION)

TABLE 419 TURKEY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 420 TURKEY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 421 BELGIUM, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 422 BELGIUM, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 423 BELGIUM, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 424 BELGIUM, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 425 BELGIUM, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 426 BELGIUM, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 427 BELGIUM, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 428 BELGIUM, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 429 BELGIUM, BY GENDER, 2018-2025 (USD MILLION)

TABLE 430 BELGIUM, BY GENDER, 2026-2033 (USD MILLION)

TABLE 431 BELGIUM, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 432 BELGIUM, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 433 BELGIUM, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 434 BELGIUM, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 435 BELGIUM, BY END USER, 2018-2025 (USD MILLION)

TABLE 436 BELGIUM, BY END USER, 2026-2033 (USD MILLION)

TABLE 437 BELGIUM, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 438 BELGIUM, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 439 NETHERLANDS, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 440 NETHERLANDS, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 441 NETHERLANDS, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 442 NETHERLANDS, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 443 NETHERLANDS, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 444 NETHERLANDS, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 445 NETHERLANDS, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 446 NETHERLANDS, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 447 NETHERLANDS, BY GENDER, 2018-2025 (USD MILLION)

TABLE 448 NETHERLANDS, BY GENDER, 2026-2033 (USD MILLION)

TABLE 449 NETHERLANDS, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 450 NETHERLANDS, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 451 NETHERLANDS, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 452 NETHERLANDS, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 453 NETHERLANDS, BY END USER, 2018-2025 (USD MILLION)

TABLE 454 NETHERLANDS, BY END USER, 2026-2033 (USD MILLION)

TABLE 455 NETHERLANDS, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 456 NETHERLANDS, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 457 DENMARK, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 458 DENMARK, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 459 DENMARK, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 460 DENMARK, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 461 DENMARK, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 462 DENMARK, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 463 DENMARK, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 464 DENMARK, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 465 DENMARK, BY GENDER, 2018-2025 (USD MILLION)

TABLE 466 DENMARK, BY GENDER, 2026-2033 (USD MILLION)

TABLE 467 DENMARK, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 468 DENMARK, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 469 DENMARK, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 470 DENMARK, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 471 DENMARK, BY END USER, 2018-2025 (USD MILLION)

TABLE 472 DENMARK, BY END USER, 2026-2033 (USD MILLION)

TABLE 473 DENMARK, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 474 DENMARK, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 475 NORWAY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 476 NORWAY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 477 NORWAY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 478 NORWAY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 479 NORWAY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 480 NORWAY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 481 NORWAY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 482 NORWAY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 483 NORWAY, BY GENDER, 2018-2025 (USD MILLION)

TABLE 484 NORWAY, BY GENDER, 2026-2033 (USD MILLION)

TABLE 485 NORWAY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 486 NORWAY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 487 NORWAY, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 488 NORWAY, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 489 NORWAY, BY END USER, 2018-2025 (USD MILLION)

TABLE 490 NORWAY, BY END USER, 2026-2033 (USD MILLION)

TABLE 491 NORWAY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 492 NORWAY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 493 FINLAND, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 494 FINLAND, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 495 FINLAND, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 496 FINLAND, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 497 FINLAND, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 498 FINLAND, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 499 FINLAND, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 500 FINLAND, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 501 FINLAND, BY GENDER, 2018-2025 (USD MILLION)

TABLE 502 FINLAND, BY GENDER, 2026-2033 (USD MILLION)

TABLE 503 FINLAND, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 504 FINLAND, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 505 FINLAND, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 506 FINLAND, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 507 FINLAND, BY END USER, 2018-2025 (USD MILLION)

TABLE 508 FINLAND, BY END USER, 2026-2033 (USD MILLION)

TABLE 509 FINLAND, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 510 FINLAND, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 511 SWEDEN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 512 SWEDEN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 513 SWEDEN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 514 SWEDEN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 515 SWEDEN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 516 SWEDEN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 517 SWEDEN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 518 SWEDEN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 519 SWEDEN, BY GENDER, 2018-2025 (USD MILLION)

TABLE 520 SWEDEN, BY GENDER, 2026-2033 (USD MILLION)

TABLE 521 SWEDEN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 522 SWEDEN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 523 SWEDEN, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 524 SWEDEN, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 525 SWEDEN, BY END USER, 2018-2025 (USD MILLION)

TABLE 526 SWEDEN, BY END USER, 2026-2033 (USD MILLION)

TABLE 527 SWEDEN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 528 SWEDEN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 529 REST OF EUROPE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 530 REST OF EUROPE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 531 REST OF EUROPE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 532 REST OF EUROPE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 533 REST OF EUROPE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 534 REST OF EUROPE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 535 REST OF EUROPE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 536 REST OF EUROPE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 537 REST OF EUROPE, BY GENDER, 2018-2025 (USD MILLION)

TABLE 538 REST OF EUROPE, BY GENDER, 2026-2033 (USD MILLION)

TABLE 539 REST OF EUROPE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 540 REST OF EUROPE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 541 REST OF EUROPE, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 542 REST OF EUROPE, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 543 REST OF EUROPE, BY END USER, 2018-2025 (USD MILLION)

TABLE 544 REST OF EUROPE, BY END USER, 2026-2033 (USD MILLION)

TABLE 545 REST OF EUROPE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 546 REST OF EUROPE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 547 ASIA PACIFIC, BY COUNTRY, 2018-2025 (USD MILLION)

TABLE 548 ASIA PACIFIC, BY COUNTRY, 2026-2033 (USD MILLION)

TABLE 549 ASIA PACIFIC, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 550 ASIA PACIFIC, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 551 ASIA PACIFIC, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 552 ASIA PACIFIC, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 553 ASIA PACIFIC, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 554 ASIA PACIFIC, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 555 ASIA PACIFIC, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 556 ASIA PACIFIC, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 557 ASIA PACIFIC, BY GENDER, 2018-2025 (USD MILLION)

TABLE 558 ASIA PACIFIC, BY GENDER, 2026-2033 (USD MILLION)

TABLE 559 ASIA PACIFIC, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 560 ASIA PACIFIC, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 561 ASIA PACIFIC, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 562 ASIA PACIFIC, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 563 ASIA PACIFIC, BY END USER, 2018-2025 (USD MILLION)

TABLE 564 ASIA PACIFIC, BY END USER, 2026-2033 (USD MILLION)

TABLE 565 ASIA PACIFIC, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 566 ASIA PACIFIC, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 567 JAPAN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 568 JAPAN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 569 JAPAN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 570 JAPAN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 571 JAPAN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 572 JAPAN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 573 JAPAN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 574 JAPAN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 575 JAPAN, BY GENDER, 2018-2025 (USD MILLION)

TABLE 576 JAPAN, BY GENDER, 2026-2033 (USD MILLION)

TABLE 577 JAPAN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 578 JAPAN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 579 JAPAN, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 580 JAPAN, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 581 JAPAN, BY END USER, 2018-2025 (USD MILLION)

TABLE 582 JAPAN, BY END USER, 2026-2033 (USD MILLION)

TABLE 583 JAPAN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 584 JAPAN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 585 CHINA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 586 CHINA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 587 CHINA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 588 CHINA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 589 CHINA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 590 CHINA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 591 CHINA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 592 CHINA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 593 CHINA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 594 CHINA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 595 CHINA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 596 CHINA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 597 CHINA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 598 CHINA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 599 CHINA, BY END USER, 2018-2025 (USD MILLION)

TABLE 600 CHINA, BY END USER, 2026-2033 (USD MILLION)

TABLE 601 CHINA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 602 CHINA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 603 SOUTH KOREA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 604 SOUTH KOREA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 605 SOUTH KOREA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 606 SOUTH KOREA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 607 SOUTH KOREA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 608 SOUTH KOREA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 609 SOUTH KOREA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 610 SOUTH KOREA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 611 SOUTH KOREA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 612 SOUTH KOREA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 613 SOUTH KOREA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 614 SOUTH KOREA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 615 SOUTH KOREA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 616 SOUTH KOREA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 617 SOUTH KOREA, BY END USER, 2018-2025 (USD MILLION)

TABLE 618 SOUTH KOREA, BY END USER, 2026-2033 (USD MILLION)

TABLE 619 SOUTH KOREA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 620 SOUTH KOREA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 621 INDIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 622 INDIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 623 INDIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 624 INDIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 625 INDIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 626 INDIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 627 INDIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 628 INDIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 629 INDIA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 630 INDIA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 631 INDIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 632 INDIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 633 INDIA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 634 INDIA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 635 INDIA, BY END USER, 2018-2025 (USD MILLION)

TABLE 636 INDIA, BY END USER, 2026-2033 (USD MILLION)

TABLE 637 INDIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 638 INDIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 639 SINGAPORE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 640 SINGAPORE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 641 SINGAPORE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 642 SINGAPORE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 643 SINGAPORE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 644 SINGAPORE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 645 SINGAPORE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 646 SINGAPORE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 647 SINGAPORE, BY GENDER, 2018-2025 (USD MILLION)

TABLE 648 SINGAPORE, BY GENDER, 2026-2033 (USD MILLION)

TABLE 649 SINGAPORE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 650 SINGAPORE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 651 SINGAPORE, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 652 SINGAPORE, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 653 SINGAPORE, BY END USER, 2018-2025 (USD MILLION)

TABLE 654 SINGAPORE, BY END USER, 2026-2033 (USD MILLION)

TABLE 655 SINGAPORE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 656 SINGAPORE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 657 THAILAND, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 658 THAILAND, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 659 THAILAND, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 660 THAILAND, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 661 THAILAND, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 662 THAILAND, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 663 THAILAND, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 664 THAILAND, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 665 THAILAND, BY GENDER, 2018-2025 (USD MILLION)

TABLE 666 THAILAND, BY GENDER, 2026-2033 (USD MILLION)

TABLE 667 THAILAND, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 668 THAILAND, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 669 THAILAND, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 670 THAILAND, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 671 THAILAND, BY END USER, 2018-2025 (USD MILLION)

TABLE 672 THAILAND, BY END USER, 2026-2033 (USD MILLION)

TABLE 673 THAILAND, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 674 THAILAND, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 675 INDONESIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 676 INDONESIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 677 INDONESIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 678 INDONESIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 679 INDONESIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 680 INDONESIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 681 INDONESIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 682 INDONESIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 683 INDONESIA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 684 INDONESIA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 685 INDONESIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 686 INDONESIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 687 INDONESIA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 688 INDONESIA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 689 INDONESIA, BY END USER, 2018-2025 (USD MILLION)

TABLE 690 INDONESIA, BY END USER, 2026-2033 (USD MILLION)

TABLE 691 INDONESIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 692 INDONESIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 693 MALAYSIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 694 MALAYSIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 695 MALAYSIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 696 MALAYSIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 697 MALAYSIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 698 MALAYSIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 699 MALAYSIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 700 MALAYSIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 701 MALAYSIA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 702 MALAYSIA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 703 MALAYSIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 704 MALAYSIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 705 MALAYSIA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 706 MALAYSIA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 707 MALAYSIA, BY END USER, 2018-2025 (USD MILLION)

TABLE 708 MALAYSIA, BY END USER, 2026-2033 (USD MILLION)

TABLE 709 MALAYSIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 710 MALAYSIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 711 PHILIPPINES, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 712 PHILIPPINES, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 713 PHILIPPINES, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 714 PHILIPPINES, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 715 PHILIPPINES, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 716 PHILIPPINES, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 717 PHILIPPINES, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 718 PHILIPPINES, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 719 PHILIPPINES, BY GENDER, 2018-2025 (USD MILLION)

TABLE 720 PHILIPPINES, BY GENDER, 2026-2033 (USD MILLION)

TABLE 721 PHILIPPINES, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 722 PHILIPPINES, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 723 PHILIPPINES, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 724 PHILIPPINES, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 725 PHILIPPINES, BY END USER, 2018-2025 (USD MILLION)

TABLE 726 PHILIPPINES, BY END USER, 2026-2033 (USD MILLION)

TABLE 727 PHILIPPINES, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 728 PHILIPPINES, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 729 AUSTRALIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 730 AUSTRALIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 731 AUSTRALIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 732 AUSTRALIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 733 AUSTRALIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 734 AUSTRALIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 735 AUSTRALIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 736 AUSTRALIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 737 AUSTRALIA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 738 AUSTRALIA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 739 AUSTRALIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 740 AUSTRALIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 741 AUSTRALIA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 742 AUSTRALIA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 743 AUSTRALIA, BY END USER, 2018-2025 (USD MILLION)

TABLE 744 AUSTRALIA, BY END USER, 2026-2033 (USD MILLION)

TABLE 745 AUSTRALIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 746 AUSTRALIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 747 NEW ZEALAND, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 748 NEW ZEALAND, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 749 NEW ZEALAND, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 750 NEW ZEALAND, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 751 NEW ZEALAND, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 752 NEW ZEALAND, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 753 NEW ZEALAND, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 754 NEW ZEALAND, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 755 NEW ZEALAND, BY GENDER, 2018-2025 (USD MILLION)

TABLE 756 NEW ZEALAND, BY GENDER, 2026-2033 (USD MILLION)

TABLE 757 NEW ZEALAND, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 758 NEW ZEALAND, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 759 NEW ZEALAND, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 760 NEW ZEALAND, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 761 NEW ZEALAND, BY END USER, 2018-2025 (USD MILLION)

TABLE 762 NEW ZEALAND, BY END USER, 2026-2033 (USD MILLION)

TABLE 763 NEW ZEALAND, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 764 NEW ZEALAND, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 765 HONG KONG, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 766 HONG KONG, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 767 HONG KONG, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 768 HONG KONG, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 769 HONG KONG, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 770 HONG KONG, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 771 HONG KONG, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 772 HONG KONG, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 773 HONG KONG, BY GENDER, 2018-2025 (USD MILLION)

TABLE 774 HONG KONG, BY GENDER, 2026-2033 (USD MILLION)

TABLE 775 HONG KONG, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 776 HONG KONG, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 777 HONG KONG, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 778 HONG KONG, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 779 HONG KONG, BY END USER, 2018-2025 (USD MILLION)

TABLE 780 HONG KONG, BY END USER, 2026-2033 (USD MILLION)

TABLE 781 HONG KONG, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 782 HONG KONG, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 783 TAIWAN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 784 TAIWAN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 785 TAIWAN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 786 TAIWAN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 787 TAIWAN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 788 TAIWAN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 789 TAIWAN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 790 TAIWAN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 791 TAIWAN, BY GENDER, 2018-2025 (USD MILLION)

TABLE 792 TAIWAN, BY GENDER, 2026-2033 (USD MILLION)

TABLE 793 TAIWAN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 794 TAIWAN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 795 TAIWAN, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 796 TAIWAN, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 797 TAIWAN, BY END USER, 2018-2025 (USD MILLION)

TABLE 798 TAIWAN, BY END USER, 2026-2033 (USD MILLION)

TABLE 799 TAIWAN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 800 TAIWAN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 801 REST OF ASIA-PACIFIC, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 802 REST OF ASIA-PACIFIC, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 803 REST OF ASIA-PACIFIC, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 804 REST OF ASIA-PACIFIC, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 805 REST OF ASIA-PACIFIC, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 806 REST OF ASIA-PACIFIC, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 807 REST OF ASIA-PACIFIC, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 808 REST OF ASIA-PACIFIC, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 809 REST OF ASIA-PACIFIC, BY GENDER, 2018-2025 (USD MILLION)

TABLE 810 REST OF ASIA-PACIFIC, BY GENDER, 2026-2033 (USD MILLION)

TABLE 811 REST OF ASIA-PACIFIC, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 812 REST OF ASIA-PACIFIC, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 813 REST OF ASIA-PACIFIC, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 814 REST OF ASIA-PACIFIC, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 815 REST OF ASIA-PACIFIC, BY END USER, 2018-2025 (USD MILLION)

TABLE 816 REST OF ASIA-PACIFIC, BY END USER, 2026-2033 (USD MILLION)

TABLE 817 REST OF ASIA-PACIFIC, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 818 REST OF ASIA-PACIFIC, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 819 SOUTH AMERICA, BY COUNTRY, 2018-2025 (USD MILLION)

TABLE 820 SOUTH AMERICA, BY COUNTRY, 2026-2033 (USD MILLION)

TABLE 821 SOUTH AMERICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 822 SOUTH AMERICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 823 SOUTH AMERICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 824 SOUTH AMERICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 825 SOUTH AMERICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 826 SOUTH AMERICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 827 SOUTH AMERICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 828 SOUTH AMERICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 829 SOUTH AMERICA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 830 SOUTH AMERICA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 831 SOUTH AMERICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 832 SOUTH AMERICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 833 SOUTH AMERICA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 834 SOUTH AMERICA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 835 SOUTH AMERICA, BY END USER, 2018-2025 (USD MILLION)

TABLE 836 SOUTH AMERICA, BY END USER, 2026-2033 (USD MILLION)

TABLE 837 SOUTH AMERICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 838 SOUTH AMERICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 839 ARGENTINA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 840 ARGENTINA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 841 ARGENTINA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 842 ARGENTINA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 843 ARGENTINA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 844 ARGENTINA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 845 ARGENTINA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 846 ARGENTINA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 847 ARGENTINA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 848 ARGENTINA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 849 ARGENTINA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 850 ARGENTINA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 851 ARGENTINA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 852 ARGENTINA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 853 ARGENTINA, BY END USER, 2018-2025 (USD MILLION)

TABLE 854 ARGENTINA, BY END USER, 2026-2033 (USD MILLION)

TABLE 855 ARGENTINA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 856 ARGENTINA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 857 BOLIVIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 858 BOLIVIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 859 BOLIVIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 860 BOLIVIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 861 BOLIVIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 862 BOLIVIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 863 BOLIVIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 864 BOLIVIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 865 BOLIVIA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 866 BOLIVIA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 867 BOLIVIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 868 BOLIVIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 869 BOLIVIA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 870 BOLIVIA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 871 BOLIVIA, BY END USER, 2018-2025 (USD MILLION)

TABLE 872 BOLIVIA, BY END USER, 2026-2033 (USD MILLION)

TABLE 873 BOLIVIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 874 BOLIVIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 875 BRAZIL, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 876 BRAZIL, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 877 BRAZIL, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 878 BRAZIL, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 879 BRAZIL, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 880 BRAZIL, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 881 BRAZIL, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 882 BRAZIL, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 883 BRAZIL, BY GENDER, 2018-2025 (USD MILLION)

TABLE 884 BRAZIL, BY GENDER, 2026-2033 (USD MILLION)

TABLE 885 BRAZIL, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 886 BRAZIL, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 887 BRAZIL, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 888 BRAZIL, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 889 BRAZIL, BY END USER, 2018-2025 (USD MILLION)

TABLE 890 BRAZIL, BY END USER, 2026-2033 (USD MILLION)

TABLE 891 BRAZIL, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 892 BRAZIL, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 893 CHILE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 894 CHILE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 895 CHILE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 896 CHILE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 897 CHILE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 898 CHILE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 899 CHILE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 900 CHILE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 901 CHILE, BY GENDER, 2018-2025 (USD MILLION)

TABLE 902 CHILE, BY GENDER, 2026-2033 (USD MILLION)

TABLE 903 CHILE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 904 CHILE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 905 CHILE, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 906 CHILE, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 907 CHILE, BY END USER, 2018-2025 (USD MILLION)

TABLE 908 CHILE, BY END USER, 2026-2033 (USD MILLION)

TABLE 909 CHILE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 910 CHILE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 911 COLOMBIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 912 COLOMBIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 913 COLOMBIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 914 COLOMBIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 915 COLOMBIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 916 COLOMBIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 917 COLOMBIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 918 COLOMBIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 919 COLOMBIA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 920 COLOMBIA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 921 COLOMBIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 922 COLOMBIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 923 COLOMBIA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 924 COLOMBIA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 925 COLOMBIA, BY END USER, 2018-2025 (USD MILLION)

TABLE 926 COLOMBIA, BY END USER, 2026-2033 (USD MILLION)

TABLE 927 COLOMBIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 928 COLOMBIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 929 ECUADOR, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 930 ECUADOR, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 931 ECUADOR, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 932 ECUADOR, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 933 ECUADOR, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 934 ECUADOR, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 935 ECUADOR, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 936 ECUADOR, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 937 ECUADOR, BY GENDER, 2018-2025 (USD MILLION)

TABLE 938 ECUADOR, BY GENDER, 2026-2033 (USD MILLION)

TABLE 939 ECUADOR, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 940 ECUADOR, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 941 ECUADOR, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 942 ECUADOR, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 943 ECUADOR, BY END USER, 2018-2025 (USD MILLION)

TABLE 944 ECUADOR, BY END USER, 2026-2033 (USD MILLION)

TABLE 945 ECUADOR, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 946 ECUADOR, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 947 PARAGUAY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 948 PARAGUAY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 949 PARAGUAY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 950 PARAGUAY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 951 PARAGUAY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 952 PARAGUAY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 953 PARAGUAY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 954 PARAGUAY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 955 PARAGUAY, BY GENDER, 2018-2025 (USD MILLION)

TABLE 956 PARAGUAY, BY GENDER, 2026-2033 (USD MILLION)

TABLE 957 PARAGUAY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 958 PARAGUAY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 959 PARAGUAY, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 960 PARAGUAY, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 961 PARAGUAY, BY END USER, 2018-2025 (USD MILLION)

TABLE 962 PARAGUAY, BY END USER, 2026-2033 (USD MILLION)

TABLE 963 PARAGUAY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 964 PARAGUAY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 965 PERU, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 966 PERU, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 967 PERU, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 968 PERU, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 969 PERU, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 970 PERU, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 971 PERU, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 972 PERU, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 973 PERU, BY GENDER, 2018-2025 (USD MILLION)

TABLE 974 PERU, BY GENDER, 2026-2033 (USD MILLION)

TABLE 975 PERU, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 976 PERU, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 977 PERU, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 978 PERU, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 979 PERU, BY END USER, 2018-2025 (USD MILLION)

TABLE 980 PERU, BY END USER, 2026-2033 (USD MILLION)

TABLE 981 PERU, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 982 PERU, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 983 URUGUAY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 984 URUGUAY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 985 URUGUAY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 986 URUGUAY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 987 URUGUAY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 988 URUGUAY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 989 URUGUAY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 990 URUGUAY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 991 URUGUAY, BY GENDER, 2018-2025 (USD MILLION)

TABLE 992 URUGUAY, BY GENDER, 2026-2033 (USD MILLION)

TABLE 993 URUGUAY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 994 URUGUAY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 995 URUGUAY, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 996 URUGUAY, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 997 URUGUAY, BY END USER, 2018-2025 (USD MILLION)

TABLE 998 URUGUAY, BY END USER, 2026-2033 (USD MILLION)

TABLE 999 URUGUAY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1000 URUGUAY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1001 VENEZUELA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1002 VENEZUELA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1003 VENEZUELA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1004 VENEZUELA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1005 VENEZUELA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1006 VENEZUELA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1007 VENEZUELA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1008 VENEZUELA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1009 VENEZUELA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1010 VENEZUELA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1011 VENEZUELA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1012 VENEZUELA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1013 VENEZUELA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1014 VENEZUELA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1015 VENEZUELA, BY END USER, 2018-2025 (USD MILLION)

TABLE 1016 VENEZUELA, BY END USER, 2026-2033 (USD MILLION)

TABLE 1017 VENEZUELA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1018 VENEZUELA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1019 REST OF SOUTH AMERICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1020 REST OF SOUTH AMERICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1021 REST OF SOUTH AMERICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1022 REST OF SOUTH AMERICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1023 REST OF SOUTH AMERICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1024 REST OF SOUTH AMERICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1025 REST OF SOUTH AMERICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1026 REST OF SOUTH AMERICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1027 REST OF SOUTH AMERICA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1028 REST OF SOUTH AMERICA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1029 REST OF SOUTH AMERICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1030 REST OF SOUTH AMERICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1031 REST OF SOUTH AMERICA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1032 REST OF SOUTH AMERICA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1033 REST OF SOUTH AMERICA, BY END USER, 2018-2025 (USD MILLION)

TABLE 1034 REST OF SOUTH AMERICA, BY END USER, 2026-2033 (USD MILLION)

TABLE 1035 REST OF SOUTH AMERICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1036 REST OF SOUTH AMERICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1037 MIDDLE EAST AND AFRICA, BY COUNTRY, 2018-2025 (USD MILLION)

TABLE 1038 MIDDLE EAST AND AFRICA, BY COUNTRY, 2026-2033 (USD MILLION)

TABLE 1039 MIDDLE EAST AND AFRICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1040 MIDDLE EAST AND AFRICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1041 MIDDLE EAST AND AFRICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1042 MIDDLE EAST AND AFRICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1043 MIDDLE EAST AND AFRICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1044 MIDDLE EAST AND AFRICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1045 EAST AND AFRICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1046 MIDDLE EAST AND AFRICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1047 MIDDLE EAST AND AFRICA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1048 MIDDLE EAST AND AFRICA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1049 MIDDLE EAST AND AFRICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1050 MIDDLE EAST AND AFRICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1051 MIDDLE EAST AND AFRICA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1052 MIDDLE EAST AND AFRICA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1053 MIDDLE EAST AND AFRICA, BY END USER, 2018-2025 (USD MILLION)

TABLE 1054 MIDDLE EAST AND AFRICA, BY END USER, 2026-2033 (USD MILLION)

TABLE 1055 MIDDLE EAST AND AFRICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1056 MIDDLE EAST AND AFRICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1057 SOUTH AFRICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1058 SOUTH AFRICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1059 SOUTH AFRICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1060 SOUTH AFRICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1061 SOUTH AFRICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1062 SOUTH AFRICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1063 SOUTH AFRICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1064 SOUTH AFRICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1065 SOUTH AFRICA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1066 SOUTH AFRICA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1067 SOUTH AFRICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1068 SOUTH AFRICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1069 SOUTH AFRICA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1070 SOUTH AFRICA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1071 SOUTH AFRICA, BY END USER, 2018-2025 (USD MILLION)

TABLE 1072 SOUTH AFRICA, BY END USER, 2026-2033 (USD MILLION)

TABLE 1073 SOUTH AFRICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1074 SOUTH AFRICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1075 EGYPT, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1076 EGYPT, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1077 EGYPT, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1078 EGYPT, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1079 EGYPT, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1080 EGYPT, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1081 EGYPT, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1082 EGYPT, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1083 EGYPT, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1084 EGYPT, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1085 EGYPT, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1086 EGYPT, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1087 EGYPT, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1088 EGYPT, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1089 EGYPT, BY END USER, 2018-2025 (USD MILLION)

TABLE 1090 EGYPT, BY END USER, 2026-2033 (USD MILLION)

TABLE 1091 EGYPT, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1092 EGYPT, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1093 SAUDI ARABIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1094 SAUDI ARABIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1095 SAUDI ARABIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1096 SAUDI ARABIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1097 SAUDI ARABIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1098 SAUDI ARABIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1099 SAUDI ARABIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1100 SAUDI ARABIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1101 SAUDI ARABIA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1102 SAUDI ARABIA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1103 SAUDI ARABIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1104 SAUDI ARABIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1105 SAUDI ARABIA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1106 SAUDI ARABIA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1107 SAUDI ARABIA, BY END USER, 2018-2025 (USD MILLION)

TABLE 1108 SAUDI ARABIA, BY END USER, 2026-2033 (USD MILLION)

TABLE 1109 SAUDI ARABIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1110 SAUDI ARABIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1111 UNITED ARAB EMIRATES, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1112 UNITED ARAB EMIRATES, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1113 UNITED ARAB EMIRATES, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1114 UNITED ARAB EMIRATES, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1115 UNITED ARAB EMIRATES, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1116 UNITED ARAB EMIRATES, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1117 UNITED ARAB EMIRATES, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1118 UNITED ARAB EMIRATES, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1119 UNITED ARAB EMIRATES, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1120 UNITED ARAB EMIRATES, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1121 UNITED ARAB EMIRATES, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1122 UNITED ARAB EMIRATES, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1123 UNITED ARAB EMIRATES, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1124 UNITED ARAB EMIRATES, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1125 UNITED ARAB EMIRATES, BY END USER, 2018-2025 (USD MILLION)

TABLE 1126 UNITED ARAB EMIRATES, BY END USER, 2026-2033 (USD MILLION)

TABLE 1127 UNITED ARAB EMIRATES, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1128 UNITED ARAB EMIRATES, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1129 ISRAEL, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1130 ISRAEL, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1131 ISRAEL, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1132 ISRAEL, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1133 ISRAEL, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1134 ISRAEL, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1135 ISRAEL, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1136 ISRAEL, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1137 ISRAEL, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1138 ISRAEL, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1139 ISRAEL, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1140 ISRAEL, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1141 ISRAEL, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1142 ISRAEL, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1143 ISRAEL, BY END USER, 2018-2025 (USD MILLION)

TABLE 1144 ISRAEL, BY END USER, 2026-2033 (USD MILLION)

TABLE 1145 ISRAEL, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1146 ISRAEL, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1147 BAHRAIN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1148 BAHRAIN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1149 BAHRAIN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1150 BAHRAIN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1151 BAHRAIN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1152 BAHRAIN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1153 BAHRAIN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1154 BAHRAIN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1155 BAHRAIN, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1156 BAHRAIN, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1157 BAHRAIN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1158 BAHRAIN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1159 BAHRAIN, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1160 BAHRAIN, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1161 BAHRAIN, BY END USER, 2018-2025 (USD MILLION)

TABLE 1162 BAHRAIN, BY END USER, 2026-2033 (USD MILLION)

TABLE 1163 BAHRAIN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1164 BAHRAIN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1165 KUWAIT, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1166 KUWAIT, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1167 KUWAIT, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1168 KUWAIT, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1169 KUWAIT, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1170 KUWAIT, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1171 KUWAIT, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1172 KUWAIT, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1173 KUWAIT, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1174 KUWAIT, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1175 KUWAIT, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1176 KUWAIT, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1177 KUWAIT, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1178 KUWAIT, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1179 KUWAIT, BY END USER, 2018-2025 (USD MILLION)

TABLE 1180 KUWAIT, BY END USER, 2026-2033 (USD MILLION)

TABLE 1181 KUWAIT, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1182 KUWAIT, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1183 OMAN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1184 OMAN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1185 OMAN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1186 OMAN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1187 OMAN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1188 OMAN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1189 OMAN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1190 OMAN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1191 OMAN, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1192 OMAN, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1193 OMAN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1194 OMAN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1195 OMAN, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1196 OMAN, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1197 OMAN, BY END USER, 2018-2025 (USD MILLION)

TABLE 1198 OMAN, BY END USER, 2026-2033 (USD MILLION)

TABLE 1199 OMAN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1200 OMAN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1201 QATAR, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1202 QATAR, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1203 QATAR, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1204 QATAR, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1205 QATAR, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1206 QATAR, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1207 QATAR, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1208 QATAR, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1209 QATAR, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1210 QATAR, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1211 QATAR, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1212 QATAR, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1213 QATAR, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1214 QATAR, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1215 QATAR, BY END USER, 2018-2025 (USD MILLION)

TABLE 1216 QATAR, BY END USER, 2026-2033 (USD MILLION)

TABLE 1217 QATAR, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1218 QATAR, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1219 REST OF MIDDLE EAST & AFRICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)

TABLE 1220 REST OF MIDDLE EAST & AFRICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)

TABLE 1221 REST OF MIDDLE EAST & AFRICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)

TABLE 1222 REST OF MIDDLE EAST & AFRICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)

TABLE 1223 REST OF MIDDLE EAST & AFRICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)

TABLE 1224 REST OF MIDDLE EAST & AFRICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)

TABLE 1225 REST OF MIDDLE EAST & AFRICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)

TABLE 1226 REST OF MIDDLE EAST & AFRICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)

TABLE 1227 REST OF MIDDLE EAST & AFRICA, BY GENDER, 2018-2025 (USD MILLION)

TABLE 1228 REST OF MIDDLE EAST & AFRICA, BY GENDER, 2026-2033 (USD MILLION)

TABLE 1229 REST OF MIDDLE EAST & AFRICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)

TABLE 1230 REST OF MIDDLE EAST & AFRICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)

TABLE 1231 REST OF MIDDLE EAST & AFRICA, BY AGE GROUP, 2018-2025 (USD MILLION)

TABLE 1232 REST OF MIDDLE EAST & AFRICA, BY AGE GROUP, 2026-2033 (USD MILLION)

TABLE 1233 REST OF MIDDLE EAST & AFRICA, BY END USER, 2018-2025 (USD MILLION)

TABLE 1234 REST OF MIDDLE EAST & AFRICA, BY END USER, 2026-2033 (USD MILLION)

TABLE 1235 REST OF MIDDLE EAST & AFRICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)

TABLE 1236 REST OF MIDDLE EAST & AFRICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)

TABLE 1237 GLOBAL CONTRACEPTIVE MARKET: COMPANY SHARE, 2025

TABLE 1238 GLOBAL CONTRACEPTIVE MARKET: MERGERS & ACQUISITIONS

TABLE 1239 GLOBAL CONTRACEPTIVE MARKET: NEW PRODUCT DEVELOPMENT & APPROVALS

TABLE 1240 GLOBAL CONTRACEPTIVE MARKET: EXPANSIONS

TABLE 1241 GLOBAL CONTRACEPTIVE MARKET: PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

TABLE 1242 GLOBAL CONTRACEPTIVE MARKET: STRENGTHS AND WEAKNESSES

TABLE 1243 GLOBAL CONTRACEPTIVE MARKET: OPPORTUNITIES AND THREATS

TABLE 1244 BAYER AG: PRODUCT PORTFOLIO

TABLE 1245 BAYER AG: RECENT DEVELOPMENTS

TABLE 1246 BAYER AG: RECENT NEWS

TABLE 1247 ORGANON & CO.: PRODUCT PORTFOLIO

TABLE 1248 ORGANON & CO.: RECENT DEVELOPMENTS

TABLE 1249 ORGANON & CO.: RECENT NEWS

TABLE 1250 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 1251 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS

TABLE 1252 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT NEWS

TABLE 1253 PFIZER INC.: PRODUCT PORTFOLIO

TABLE 1254 PFIZER INC.: RECENT DEVELOPMENTS

TABLE 1255 PFIZER INC.: RECENT NEWS

TABLE 1256 GEDEON RICHTER PLC.: PRODUCT PORTFOLIO

TABLE 1257 GEDEON RICHTER PLC.: RECENT DEVELOPMENTS

TABLE 1258 GEDEON RICHTER PLC.: RECENT NEWS

TABLE 1259 VIATRIS INC.: PRODUCT PORTFOLIO

TABLE 1260 VIATRIS INC.: RECENT DEVELOPMENTS

TABLE 1261 VIATRIS INC.: RECENT NEWS

TABLE 1262 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 1263 SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS

TABLE 1264 SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT NEWS

TABLE 1265 LUPIN: PRODUCT PORTFOLIO

TABLE 1266 LUPIN: RECENT DEVELOPMENTS

TABLE 1267 LUPIN: RECENT NEWS

TABLE 1268 GLENMARK PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 1269 GLENMARK PHARMACEUTICALS: RECENT DEVELOPMENTS

TABLE 1270 GLENMARK PHARMACEUTICALS: RECENT NEWS

TABLE 1271 CIPLA: PRODUCT PORTFOLIO

TABLE 1272 CIPLA: RECENT DEVELOPMENTS

TABLE 1273 CIPLA: RECENT NEWS

TABLE 1274 APOTEX INC.: PRODUCT PORTFOLIO

TABLE 1275 APOTEX INC.: RECENT DEVELOPMENTS

TABLE 1276 APOTEX INC.: RECENT NEWS

TABLE 1277 INSUD PHARMA, S.L.: PRODUCT PORTFOLIO

TABLE 1278 INSUD PHARMA, S.L.: RECENT DEVELOPMENTS

TABLE 1279 INSUD PHARMA, S.L.: RECENT NEWS

TABLE 1280 COOPERSURGICAL, INC.: PRODUCT PORTFOLIO

TABLE 1281 COOPERSURGICAL, INC.: RECENT DEVELOPMENTS

TABLE 1282 COOPERSURGICAL, INC.: RECENT NEWS

TABLE 1283 MANKIND: PRODUCT PORTFOLIO

TABLE 1284 MANKIND: RECENT DEVELOPMENTS

TABLE 1285 MANKIND: RECENT NEWS

TABLE 1286 CHURCH & DWIGHT CO., INC.: PRODUCT PORTFOLIO

TABLE 1287 CHURCH & DWIGHT CO., INC.: RECENT DEVELOPMENTS

TABLE 1288 CHURCH & DWIGHT CO., INC.: RECENT NEWS

TABLE 1289 RECKITT: PRODUCT PORTFOLIO

TABLE 1290 RECKITT: RECENT DEVELOPMENTS

TABLE 1291 RECKITT: RECENT NEWS

TABLE 1292 OKAMOTO INDUSTRIES, INC.: PRODUCT PORTFOLIO

TABLE 1293 OKAMOTO INDUSTRIES, INC.: RECENT DEVELOPMENTS

TABLE 1294 OKAMOTO INDUSTRIES, INC.: RECENT NEWS

TABLE 1295 SAGAMI RUBBER INDUSTRIES CO., LTD.: PRODUCT PORTFOLIO

TABLE 1296 SAGAMI RUBBER INDUSTRIES CO., LTD.: RECENT DEVELOPMENTS

TABLE 1297 SAGAMI RUBBER INDUSTRIES CO., LTD.: RECENT NEWS

TABLE 1298 FUJI LATEX CO., LTD.: PRODUCT PORTFOLIO

TABLE 1299 FUJI LATEX CO., LTD.: RECENT DEVELOPMENTS

TABLE 1300 FUJI LATEX CO., LTD.: RECENT NEWS

TABLE 1301 KAREX BERHAD: PRODUCT PORTFOLIO

TABLE 1302 KAREX BERHAD: RECENT DEVELOPMENTS

TABLE 1303 KAREX BERHAD: RECENT NEWS

TABLE 1304 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED: PRODUCT PORTFOLIO

TABLE 1305 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED: RECENT DEVELOPMENTS

TABLE 1306 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED: RECENT NEWS

TABLE 1307 MAYER LABORATORIES, INC.: PRODUCT PORTFOLIO

TABLE 1308 MAYER LABORATORIES, INC.: RECENT DEVELOPMENTS

TABLE 1309 MAYER LABORATORIES, INC.: RECENT NEWS

TABLE 1310 CUPID: PRODUCT PORTFOLIO

TABLE 1311 CUPID: RECENT DEVELOPMENTS

TABLE 1312 CUPID: RECENT NEWS

TABLE 1313 TTK: PRODUCT PORTFOLIO

TABLE 1314 TTK: RECENT DEVELOPMENTS

TABLE 1315 TTK: RECENT NEWS

TABLE 1316 PREGNA INTERNATIONAL LIMITED: PRODUCT PORTFOLIO

TABLE 1317 PREGNA INTERNATIONAL LIMITED: RECENT DEVELOPMENTS

TABLE 1318 PREGNA INTERNATIONAL LIMITED: RECENT NEWS

TABLE 1319 SMB CORPORATION OF INDIA: PRODUCT PORTFOLIO

TABLE 1320 SMB CORPORATION OF INDIA: RECENT DEVELOPMENTS

TABLE 1321 SMB CORPORATION OF INDIA: RECENT NEWS

TABLE 1322 EUROGINE: PRODUCT PORTFOLIO

TABLE 1323 EUROGINE: RECENT DEVELOPMENTS

TABLE 1324 EUROGINE: RECENT NEWS

TABLE 1325 OCON MEDICAL LTD.: PRODUCT PORTFOLIO

TABLE 1326 OCON MEDICAL LTD.: RECENT DEVELOPMENTS

TABLE 1327 OCON MEDICAL LTD.: RECENT NEWS

TABLE 1328 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO

TABLE 1329 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS

TABLE 1330 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.: RECENT NEWS

TABLE 1331 HLL LIFECARE LIMITED: PRODUCT PORTFOLIO

TABLE 1332 HLL LIFECARE LIMITED: RECENT DEVELOPMENTS

TABLE 1333 HLL LIFECARE LIMITED: RECENT NEWS

List of Figure

FIGURE 1 GLOBAL CONTRACEPTIVE MARKET: SEGMENTATION

FIGURE 2 MARKET COVERAGE GRID: ROUTES TO MARKET EVIDENCED IN PUBLISHED SOURCES

FIGURE 3 GLOBAL CONTRACEPTIVE MARKET, 2018-2033 (USD MILLION)

FIGURE 4 GLOBAL CONTRACEPTIVE MARKET: SEGMENTATION AT A GLANCE, 2025

FIGURE 5 GLOBAL CONTRACEPTIVE MARKET: KEY FINDINGS

FIGURE 6 GLOBAL CONTRACEPTIVE MARKET: DRIVERS IMPACT RADAR

FIGURE 7 GLOBAL CONTRACEPTIVE MARKET: PORTER'S FIVE FORCES

FIGURE 8 GLOBAL CONTRACEPTIVE MARKET: PESTLE ANALYSIS

FIGURE 9 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE: KEY FINDINGS

FIGURE 10 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2025

FIGURE 11 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2033 (USD MILLION)

FIGURE 12 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION: KEY FINDINGS

FIGURE 13 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION, 2025

FIGURE 14 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION: KEY FINDINGS

FIGURE 15 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION, 2025

FIGURE 16 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION: KEY FINDINGS

FIGURE 17 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION, 2025

FIGURE 18 GLOBAL CONTRACEPTIVE MARKET, BY GENDER: KEY FINDINGS

FIGURE 19 GLOBAL CONTRACEPTIVE MARKET, BY GENDER, 2025

FIGURE 20 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS: KEY FINDINGS

FIGURE 21 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS, 2025

FIGURE 22 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP: KEY FINDINGS

FIGURE 23 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2025

FIGURE 24 GLOBAL CONTRACEPTIVE MARKET, BY END USER: KEY FINDINGS

FIGURE 25 GLOBAL CONTRACEPTIVE MARKET, BY END USER, 2025

FIGURE 26 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL: KEY FINDINGS

FIGURE 27 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL, 2025

FIGURE 28 GLOBAL CONTRACEPTIVE MARKET, BY REGION: KEY FINDINGS

FIGURE 29 GLOBAL CONTRACEPTIVE MARKET, BY REGION, 2025

FIGURE 30 NORTH AMERICA, BY COUNTRY, 2025

FIGURE 31 EUROPE, BY COUNTRY, 2025

FIGURE 32 ASIA PACIFIC, BY COUNTRY, 2025

FIGURE 33 SOUTH AMERICA, BY COUNTRY, 2025

FIGURE 34 MIDDLE EAST AND AFRICA, BY COUNTRY, 2025

FIGURE 35 ESTIMATED COMPANY SHARE, GLOBAL CONTRACEPTIVE, 2025 (%)

FIGURE 36 GLOBAL CONTRACEPTIVE: SWOT ANALYSIS

FIGURE 37 BAYER AG, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 38 BAYER AG: COMPANY SNAPSHOT

FIGURE 39 ORGANON & CO., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 40 ORGANON & CO.: COMPANY SNAPSHOT

FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

FIGURE 43 PFIZER INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT

FIGURE 45 GEDEON RICHTER PLC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 46 GEDEON RICHTER PLC.: COMPANY SNAPSHOT

FIGURE 47 VIATRIS INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 48 VIATRIS INC.: COMPANY SNAPSHOT

FIGURE 49 SUN PHARMACEUTICAL INDUSTRIES LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 50 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

FIGURE 51 LUPIN, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 52 LUPIN: COMPANY SNAPSHOT

FIGURE 53 GLENMARK PHARMACEUTICALS, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 54 GLENMARK PHARMACEUTICALS: COMPANY SNAPSHOT

FIGURE 55 CIPLA, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 56 CIPLA: COMPANY SNAPSHOT

FIGURE 57 APOTEX INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 58 APOTEX INC.: COMPANY SNAPSHOT

FIGURE 59 INSUD PHARMA, S.L., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 60 INSUD PHARMA, S.L.: COMPANY SNAPSHOT

FIGURE 61 COOPERSURGICAL, INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 62 COOPERSURGICAL, INC.: COMPANY SNAPSHOT

FIGURE 63 MANKIND, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 64 MANKIND: COMPANY SNAPSHOT

FIGURE 65 CHURCH & DWIGHT CO., INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 66 CHURCH & DWIGHT CO., INC.: COMPANY SNAPSHOT

FIGURE 67 RECKITT, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 68 RECKITT: COMPANY SNAPSHOT

FIGURE 69 OKAMOTO INDUSTRIES, INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 70 OKAMOTO INDUSTRIES, INC.: COMPANY SNAPSHOT

FIGURE 71 SAGAMI RUBBER INDUSTRIES CO., LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 72 SAGAMI RUBBER INDUSTRIES CO., LTD.: COMPANY SNAPSHOT

FIGURE 73 FUJI LATEX CO., LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 74 FUJI LATEX CO., LTD.: COMPANY SNAPSHOT

FIGURE 75 KAREX BERHAD, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 76 KAREX BERHAD: COMPANY SNAPSHOT

FIGURE 77 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 78 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED: COMPANY SNAPSHOT

FIGURE 79 MAYER LABORATORIES, INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 80 MAYER LABORATORIES, INC.: COMPANY SNAPSHOT

FIGURE 81 CUPID, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 82 CUPID: COMPANY SNAPSHOT

FIGURE 83 TTK, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 84 TTK: COMPANY SNAPSHOT

FIGURE 85 PREGNA INTERNATIONAL LIMITED, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 86 PREGNA INTERNATIONAL LIMITED: COMPANY SNAPSHOT

FIGURE 87 SMB CORPORATION OF INDIA, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 88 SMB CORPORATION OF INDIA: COMPANY SNAPSHOT

FIGURE 89 EUROGINE, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 90 EUROGINE: COMPANY SNAPSHOT

FIGURE 91 OCON MEDICAL LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 92 OCON MEDICAL LTD.: COMPANY SNAPSHOT

FIGURE 93 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 94 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT

FIGURE 95 HLL LIFECARE LIMITED, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025

FIGURE 96 HLL LIFECARE LIMITED: COMPANY SNAPSHOT

View Detailed Information

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The contraceptive market was valued at USD 8.67 billion in 2025

The contraceptive market is projected to grow at a compound annual growth rate (CAGR) of 2.40% during the forecast period from 2026 to 2033, driven by increasing awareness of reproductive health, rising demand for effective pregnancy prevention methods, and expanding family planning initiatives. Growing adoption of oral contraceptives, contraceptive devices, and long-acting reversible contraceptives, along with improved access through healthcare facilities, retail pharmacies, and online platforms, is expected to support market growth during the forecast period.

The North America region dominated the contraceptive market with the largest revenue share of 39.28% in 2025, supported by established healthcare infrastructure, increasing awareness of reproductive health, and widespread availability of contraceptive products. Strong access to family planning services, retail pharmacies, and prescription-based healthcare, along with growing adoption of modern contraceptive methods, further strengthened regional market demand.

The Middle East And Africa region is expected to be the fastest-growing region in the contraceptive market, registering a CAGR of 3.95% during 2026–2033. Growth is supported by increasing awareness of family planning, expanding reproductive healthcare initiatives, and improving access to contraceptive products. Government programs and healthcare organizations promoting pregnancy prevention are further contributing to regional market development.

The contraceptive market is the rising focus on preventing unplanned pregnancy and family planning, government initiatives and funding, longer licensed durations lifting demand for long-acting reversible methods, pharmacy and over-the-counter access removing the prescription step, new product approvals widening the method mix beyond the pill and the hormonal IUD

Author

Tauqeer Ahmad in

Associate Manager

Tauqeer Ahmad is an Associate Manager within the Healthcare Practice at Data Bridge Market Research, bringing over eight years of experience in delivering strategic intelligence across pharmaceuticals, biotechnology, medical devices, and healthcare IT domains. He specializes in translating complex market dynamics into actionable insights that support critical business decisions for global clients.

Speak to Analyst

Industry Related Reports